Edgar Filing: Prestige Brands Holdings, Inc.

PBH 10Q December 31, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



[ X ]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2013



[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to _____

Commission File Number: 001-32433

PRESTIGE BRANDS HOLDINGS, INC.

(Exact name of Registrant as specified in its charter)



Delaware		20-1297589
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

660 White Plains Road

Tarrytown, New York 10591

(Address of principal executive offices) (Zip Code)

(914) 524-6800

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer x		Accelerated filer o
Non-accelerated filer o	(Do not check if a smaller reporting company)	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

As of January 31, 2014, there were 51,800,179 shares of common stock outstanding.

Prestige Brands Holdings, Inc.

Form 10-Q

Index



PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements
	Consolidated Statements of Income and Comprehensive Income for the three and nine months ended December 31, 2013 and 2012 (unaudited)	2
	Consolidated Balance Sheets as of December 31, 2013 (unaudited) and March 31, 2013	3
	Consolidated Statements of Cash Flows for the nine months ended December 31, 2013 and 2012 (unaudited)	4
	Notes to Consolidated Financial Statements (unaudited)	5

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	35

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	55

Item 4.	Controls and Procedures	55

PART II.	OTHER INFORMATION

Item 1A.	Risk Factors	55

Item 6.	Exhibits	61

	Signatures	62

Trademarks and Trade Names

Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Brands Holdings, Inc. or its subsidiaries, as the case may be. We have italicized our trademarks or trade names when they appear in this Quarterly Report on Form 10-Q.

- 1-


PART I	FINANCIAL INFORMATION


ITEM 1.	FINANCIAL STATEMENTS

Prestige Brands Holdings, Inc.

Consolidated Statements of Income and Comprehensive Income

(Unaudited)



	Three Months Ended December 31,						Nine Months Ended December 31,
(In thousands, except per share data)	2013			2012			2013			2012
Revenues
Net sales	$	145,054		$	159,492		$	454,159		$	466,735
Other revenues	1,158			740			3,466			2,349
Total revenues	146,212			160,232			457,625			469,084

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	64,403			75,235			197,614			209,938
Gross profit	81,809			84,997			260,011			259,146

Operating Expenses
Advertising and promotion	25,570			23,538			70,754			67,371
General and administrative	12,137			11,378			35,390			40,114
Depreciation and amortization	3,644			3,359			10,206			9,950
Total operating expenses	41,351			38,275			116,350			117,435
Operating income	40,458			46,722			143,661			141,711

Other (income) expense
Interest income	(16		)	(4		)	(44		)	(9		)
Interest expense	21,276			26,665			53,648			66,178
Loss on extinguishment of debt	15,012			—			15,012			—
Total other expense	36,272			26,661			68,616			66,169
Income before income taxes	4,186			20,061			75,045			75,542
Provision for income taxes	1,056			7,804			18,431			29,386
Net income	$	3,130		$	12,257		$	56,614		$	46,156

Earnings per share:
Basic	$	0.06		$	0.24		$	1.10		$	0.91
Diluted	$	0.06		$	0.24		$	1.08		$	0.90

Weighted average shares outstanding:
Basic	51,806			50,686			51,498			50,465
Diluted	52,445			51,523			52,236			51,285

Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,694		)	(1		)	(1,571		)	23
Total other comprehensive (loss) income	(2,694		)	(1		)	(1,571		)	23
Comprehensive income	$	436		$	12,256		$	55,043		$	46,179

See accompanying notes.

- 2-

Prestige Brands Holdings, Inc.

Consolidated Balance Sheets

(Unaudited)



(In thousands) Assets	December 31, 2013			March 31, 2013
Current assets
Cash and cash equivalents	$	94,353		$	15,670
Accounts receivable, net	66,188			73,053
Inventories	64,798			60,201
Deferred income tax assets	6,836			6,349
Prepaid expenses and other current assets	12,326			8,900
Total current assets	244,501			164,173

Property and equipment, net	10,528			9,896
Goodwill	189,955			167,546
Intangible assets, net	1,395,755			1,373,240
Other long-term assets	24,107			24,944
Total Assets	$	1,864,846		$	1,739,799

Liabilities and Stockholders' Equity
Current liabilities
Current portion of long-term debt	$	48,290		$	—
Accounts payable	51,547			51,376
Accrued interest payable	10,781			13,894
Other accrued liabilities	23,445			31,398
Total current liabilities	134,063			96,668

Long-term debt
Principal amount	985,000			978,000
Less unamortized discount	(3,489		)	(7,100		)
Long-term debt, net of unamortized discount	981,511			970,900

Deferred income tax liabilities	205,036			194,288
Other long-term liabilities	302			—
Total Liabilities	1,320,912			1,261,856

Commitments and Contingencies — Note 17

Stockholders' Equity
Preferred stock - $0.01 par value
Authorized - 5,000 shares
Issued and outstanding - None	—			—
Preferred share rights	283			283
Common stock - $0.01 par value
Authorized - 250,000 shares
Issued - 51,961 shares at December 31, 2013 and 51,311 shares at March 31, 2013	520			513
Additional paid-in capital	412,910			401,691
Treasury stock, at cost - 194 shares at December 31, 2013 and 181 shares March 31, 2013	(965		)	(687		)
Accumulated other comprehensive loss, net of tax	(1,675		)	(104		)
Retained earnings	132,861			76,247
Total Stockholders' Equity	543,934			477,943
Total Liabilities and Stockholders' Equity	$	1,864,846		$	1,739,799

See accompanying notes.

- 3-

Prestige Brands Holdings, Inc.

Consolidated Statements of Cash Flows

(Unaudited)



	Nine Months Ended December 31,
(In thousands)	2013			2012
Operating Activities
Net income	$	56,614		$	46,156
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	10,209			9,950
Deferred income taxes	10,261			15,979
Amortization of deferred financing costs	6,023			8,220
Stock-based compensation costs	3,763			2,965
Loss on extinguishment of debt	15,012			—
Premium payment on 2010 Senior Notes	(12,768		)	—
Amortization of debt discount	3,115			3,892
Lease termination costs	—			975
(Gain) loss on sale or disposal of property and equipment	(3		)	51

Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	8,495			(13,518		)
Inventories	(2,262		)	(3,351		)
Prepaid expenses and other current assets	(2,783		)	5,801
Accounts payable	(1,285		)	14,125
Accrued liabilities	(13,531		)	9,631
Net cash provided by operating activities	80,860			100,876

Investing Activities
Purchases of property and equipment	(2,658		)	(8,922		)
Proceeds from the sale of property and equipment	3			15
Proceeds from the sale of the Phazyme brand	—			21,700
Acquisition of brands from GSK purchase price adjustments	—			(226		)
Acquisition of Care Pharmaceuticals, less cash acquired	(55,215		)	—
Net cash (used in) provided by investing activities	(57,870		)	12,567

Financing Activities
Proceeds from the issuance of 2013 Senior Notes	400,000			—
Repayment of 2010 Senior Notes	(201,710		)	—
Repayments of long-term debt	(147,500		)	(167,500		)
Repayments under revolving credit agreement	(45,500		)	(8,000		)
Borrowings under revolving credit agreement	50,000			48,000
Payment of deferred financing costs	(6,933		)	—
Proceeds from exercise of stock options	5,738			5,460
Excess tax benefits from share-based awards	1,725			—
Fair value of shares surrendered as payment of tax withholding	(278		)	—
Net cash provided by (used in) financing activities	55,542			(122,040		)

Effects of exchange rate changes on cash and cash equivalents	151			13
Increase (decrease) in cash and cash equivalents	78,683			(8,584		)
Cash and cash equivalents - beginning of period	15,670			19,015
Cash and cash equivalents - end of period	$	94,353		$	10,431

Interest paid	$	47,586		$	54,149
Income taxes paid	$	9,761		$	7,183

See accompanying notes.

- 4-

Prestige Brands Holdings, Inc.

Notes to Consolidated Financial Statements (unaudited)


1.	Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, club, convenience, and dollar stores in the United States and Canada and in certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to the Consolidated Financial Statements.

Basis of Presentation

The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements. In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31^st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2014”) mean our fiscal year ending or ended on March 31^st of that year. Operating results for the three and nine months ended December 31, 2013 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2014. This financial information should be read in conjunction with our Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at December 31, 2013 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

- 5-

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year. If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.

Deferred Financing Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. These costs are capitalized as deferred financing costs and amortized using the effective interest method, over the term of the related debt.

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

- 6-

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs were $7.6 million and $23.3 million for the three and nine months ended December 31, 2013, respectively, and $7.6 million and $23.1 million for the three and nine months ended December 31, 2012, respectively.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period an employee or director is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

In July 2013, the FASB issued Accounting Standards Updated ("ASU") 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which requires that an unrecognized tax benefit, or portion of an unrecognized tax benefit, be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. If an applicable deferred tax asset is not available to use or the tax law of the applicable jurisdiction does not require the entity to use and the company does not intend to use the applicable deferred tax asset, the unrecognized tax benefit should be presented as a liability in the financial statements and should not be combined with an unrelated deferred tax asset. ASU 2013-11 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date; however retrospective application is permitted. The adoption of ASU 2013-11 is not expected to have a material impact on our Consolidated Financial Statements.

- 7-

of cumulative translation adjustments into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on our Consolidated Financial Statements.

In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires that for those items that are reclassified out of accumulated other comprehensive income and into net income in their entirety, the effect of the reclassification on each affected net income line item be disclosed. For accumulated other comprehensive income reclassification items that are not reclassified in their entirety into net income, a cross reference must be made to other required disclosures. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. ASU 2013-02 did not have a material impact on our Consolidated Financial Statements. See Note 13 Accumulated Other Comprehensive Loss for required disclosure.

In December 2011, the FASB issued ASU 2011-11, Disclosures about Offsetting Assets and Liabilities, regarding disclosures about offsetting assets and liabilities. The new disclosure requirements mandate that entities disclose both gross and net information about instruments and transactions eligible for offset in the statement of financial position, as well as instruments and transactions subject to an agreement similar to a master netting arrangement. In addition, the standard requires disclosure of collateral received and posted in connection with master netting agreements or similar arrangements. An entity will be required to disclose the following information for assets and liabilities within the scope of the new standard: (i) the gross amounts of those recognized assets and those recognized liabilities; (ii) the amounts offset to determine the net amounts presented in the statement of financial position; (iii) the net amounts presented in the statement of financial position; (iv) the amounts subject to an enforceable master netting arrangement or similar agreement not otherwise included in (ii); and (v) the net amount after deducting the amounts in (iv) from the amounts in (iii). The standard affects all entities with balances presented on a net basis in the financial statements, derivative assets and derivative liabilities, repurchase agreements, and financial assets and financial liabilities executed under a master netting or similar arrangement. This guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. This new guidance did not have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.


2.	Acquisitions

Acquisition of Care Pharmaceuticals Pty Ltd.

On July 1, 2013, we completed the acquisition of Care Pharmaceuticals Pty Ltd. (“Care Pharma”), which was funded through a combination of our existing senior secured credit facility and cash on hand.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also carries a line of brands for children including Little Allergies, Little Eyes, and Little Coughs. The brands acquired are complementary to our existing OTC Healthcare portfolio.

This acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared a preliminary analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.

- 8-



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,103

Accounts payable	1,537
Accrued expenses	2,505
Other long term liabilities	300
Total liabilities assumed	4,342

Net assets acquired	$	56,761

Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at December 31, 2013 was 14.1 years.

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.


3.	Divestitures

Sale of the Phazyme Brand

On October 31, 2012, we divested the Phazyme gas treatment brand, which was a non-core OTC brand that we acquired from GlaxoSmithKline ("GSK") in January 2012. We received $21.7 million from the divestiture on October 31, 2012 and the remaining $0.6 million on January 4, 2013. The proceeds were used to repay debt. No significant gain or loss was recorded as a result of the sale.

Concurrent with the completion of the sale of the Phazyme brand, we entered into a Transitional Services Agreement with the buyer (the “Phazyme TSA”), whereby we agreed to provide the buyer with various services, including marketing, operations, finance and other services, from the date of the acquisition primarily through January 31, 2013, with an option for additional support for the Canadian portion of that business through October 31, 2013, at the buyer's discretion. All Phazyme United States TSA services ended, as agreed, on January 31, 2013. The buyer elected to extend the Canadian portion of the TSA services on a month to month basis and terminated the support on October 31, 2013.

The following table presents the assets sold at October 31, 2012 related to the Phazyme brand:



(In thousands)	October 31, 2012
Components of assets sold:
Inventory	$	220
Prepaid expenses	100
Trade names	15,604
Goodwill	6,382

- 9-


4.	Accounts Receivable

Accounts receivable consist of the following:



(In thousands)	December 31, 2013			March 31, 2013
Components of Accounts Receivable
Trade accounts receivable	$	74,025		$	79,746
Other receivables	1,709			615
	75,734			80,361
Less allowances for discounts, returns and uncollectible accounts	(9,546		)	(7,308		)
Accounts receivable, net	$	66,188		$	73,053


5.	Inventories

Inventories consist of the following:



(In thousands)	December 31, 2013		March 31, 2013
Components of Inventories
Packaging and raw materials	$	1,455	$	1,875
Finished goods	63,343		58,326
Inventories	$	64,798	$	60,201

Inventories are carried at the lower of cost or market, which includes a reduction in inventory values of $2.6 million and $1.3 million at December 31, 2013 and March 31, 2013, respectively, related to obsolete and slow-moving inventory.


6.	Property and Equipment

Property and equipment consist of the following:



(In thousands)	December 31, 2013			March 31, 2013
Components of Property and Equipment
Machinery	$	1,870		$	1,580
Computer equipment and software	8,886			6,559
Furniture and fixtures	1,826			1,510
Leasehold improvements	4,732			4,713
	17,314			14,362
Accumulated depreciation	(6,786		)	(4,466		)
Property and equipment, net	$	10,528		$	9,896

We recorded depreciation expense of $1.1 million and $0.4 million for the three months ended December 31, 2013 and December 31, 2012, respectively, and $2.2 million and $1.0 million for the nine months ended December 31, 2013 and December 31, 2012, respectively. Additionally, during the nine months ended December 31, 2012, we wrote-off leasehold improvements with a remaining net book value of less than $0.1 million due to the relocation of our corporate offices.

- 10-


7.	Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:



(In thousands)	OTC Healthcare			Household Cleaning		Consolidated

Balance — March 31, 2013	$	160,157		$	7,389	$	167,546
Additions	23,122			—		23,122
Effects of foreign currency exchange rates	(713		)	—		(713		)
Balance — December 31, 2013	$	182,566		$	7,389	$	189,955

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.

On an annual basis, during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of the values assigned to goodwill and tests for impairment.

At March 31, 2013, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2013. As of December 31, 2013, there have been no triggering events that would indicate potential impairment.

The discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2013, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

- 11-


8.	Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:



(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement			Totals
Gross Carrying Amounts
Balance — March 31, 2013	$	1,243,718		$	203,066		$	158		$	1,446,942
Additions	29,845			1,657			—			31,502
Reductions	—			—			(158		)	(158		)
Effects of foreign currency exchange rates	(919		)	(51		)	—			(970		)
Balance — December 31, 2013	$	1,272,644		$	204,672		$	—		$	1,477,316

Accumulated Amortization
Balance — March 31, 2013	$	—		$	73,544		$	158		$	73,702
Additions	—			8,019			—			8,019
Reductions	—			—			(158		)	(158		)
Effects of foreign currency exchange rates	—			(2		)	—			(2		)
Balance — December 31, 2013	$	—		$	81,561		$	—		$	81,561

Intangible assets, net - December 31, 2013	$	1,272,644		$	123,111		$	—		$	1,395,755

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we allocated $31.5 million to intangible assets based on our preliminary analysis.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and must also be tested for impairment annually or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.

In a manner similar to goodwill, we completed our annual test for impairment of our indefinite-lived intangible assets during the three months ended March 31, 2013. We did not record an impairment charge, as facts and circumstances indicated that the fair values of the intangible assets for our brands exceeded their carrying values. Additionally, for the indefinite-lived intangible assets, an evaluation of the facts and circumstances as of December 31, 2013 continues to support an indefinite useful life for these assets. Therefore, no impairment charge was recorded for the nine months ended December 31, 2013.

The weighted average remaining life for finite-lived intangible assets at December 31, 2013 was approximately 13.8 years and the amortization expense for the three and nine months ended December 31, 2013 was $2.6 million and $8.0 million, respectively. At December 31, 2013, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:

- 12-



(In thousands)
Year Ending March 31,	Amount
2014 (Remaining three months ending March 31, 2014)	$	2,235
2015	8,949
2016	8,949
2017	8,949
2018	8,949
Thereafter	85,080
	$	123,111


9.	Other Accrued Liabilities

Other accrued liabilities consist of the following:



(In thousands)	December 31, 2013		March 31, 2013

Accrued marketing costs	$	11,845	$	17,187
Accrued compensation costs	5,378		8,847
Accrued broker commissions	941		1,028
Income taxes payable	—		493
Accrued professional fees	3,794		1,846
Deferred rent	1,254		1,268
Accrued lease termination costs	180		729
Other accrued liabilities	53		—
	$	23,445	$	31,398


10.	Long-Term Debt

2010 Senior Notes:

On March 24, 2010, Prestige Brands, Inc. (the "Borrower") issued $150.0 million of senior unsecured notes, with an interest rate of 8.25% and a maturity date of April 1, 2018 (the "2010 Senior Notes"). On November 1, 2010, the Borrower issued an additional $100.0 million of the 2010 Senior Notes. The Borrower may earlier redeem some or all of the 2010 Senior Notes at redemption prices set forth in the indenture governing the 2010 Senior Notes. The 2010 Senior Notes issued in March and November 2010 were issued at an aggregate face value of $150.0 million and $100.0 million, respectively, with a discount to the initial purchasers of $2.2 million and a premium of $0.3 million, respectively, and net proceeds to the Company of $147.8 million and $100.3 million, respectively, yielding an 8.5% effective interest rate for the 2010 Senior Notes on a combined basis. The 2010 Senior Notes are unconditionally guaranteed by Prestige Brands Holdings, Inc. and its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. On December 17, 2013, we offered to redeem the 2010 Senior Notes at a premium of 6.33%, of which $201.7 million were redeemed on such date. The remaining $48.3 million were redeemed on January 16, 2014, which is included in our current liabilities as of December 31, 2013. As a result, during the quarter ended December 31, 2013, we recorded a $15.0 million loss on the early extinguishment of debt relating to the $201.7 million 2010 Senior Notes redeemed and will record an additional loss of approximately $3.3 million on the remaining $48.3 million tendered on January 16, 2014. This loss consists of premium payments of $12.8 million, write-off of deferred financing costs of $1.7 million, and write-off of debt discount of $0.5 million.

2012 Senior Notes:

On January 31, 2012, the Borrower issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.

- 13-

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In September 2012, we utilized a portion of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $25.0 million to $75.0 million, and in June 2013, we further increased the amount of our borrowing capacity under the 2012 ABL Revolver by $20.0 million to $95.0 million and also reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Company of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Amendment") to the 2012 Term Loan. The Amendment provides for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans. The interest rate on the Term B-1 Loans is based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin. The new Term B-1 Loans will mature on the same date as the Term B Loans' original maturity date. In addition, the Amendment provides the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with the Amendment, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

During the three months ended December 31, 2012, as a result of our significant debt repayments, we accelerated a portion of the deferred financing costs and original issue discount related to our 2012 Term Loan. As a result, during the three months ended December 31, 2012, we recorded a $7.7 million pre-tax charge to interest expense related to this non-cash acceleration. Of the $7.7 million, $3.0 million relates to the prior three quarters. Had the timing of the accelerated amortization been properly recorded, pre-tax earnings for the three and nine months ended December 31, 2012 would have been higher by $3.0 million ($1.9 million after tax, or $0.03 per diluted share) and $1.1 million ($0.7 million after tax or $0.01 per diluted share), respectively; pre-tax earnings in the first and second quarters of 2013 would have been lower by $1.2 million ($0.7 million after tax or $0.02 per diluted share) and $0.7 million ($0.5 million after tax, or $0.01 per diluted share), respectively; and pre-tax earnings in the fourth quarter of 2012 and the year ended March 31, 2012 would have been lower by $1.1 million ($0.7 million after tax, or $0.01 per diluted share). We do not believe the amounts were material to the consolidated financial statements for any prior period and the cumulative amount is not material to the estimated results of operations for the year ended March 31, 2013. Furthermore, the adjustments had no impact to our cash flows from operations or total cash flows.

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, provided that LIBOR shall not be lower than 1.00%. For the nine months ended December 31, 2013, the average interest rate on the 2012 Term Loan was 4.0%.

Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make a payment until the maturity date of January 31, 2019.

Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we

- 14-

are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments in an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the nine months ended December 31, 2013, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.0%.

We used the net proceeds from the 2012 Senior Notes offering, together with borrowings under the 2012 Term Loan, to finance the acquisition of the 17 North American OTC healthcare brands from GSK (the "GSK Brands"), to repay the balance of our then outstanding credit facility, to pay fees and expenses incurred in connection with these transactions and for general corporate purposes.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $6.7 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

Guarantees and Subordination:

The 2010 Senior Notes, which have been redeemed, are secured on a pari passu basis with the 2012 Term Loan and are guaranteed on a senior secured basis. The 2012 Senior Notes and the 2013 Senior Notes are senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis. The 2010 Senior Notes are effectively junior in right of payment to all existing and future secured obligations of the Company, equal in right of payment with all existing and future senior unsecured indebtedness of the Company, and senior in right of payment to all future subordinated debt of the Company. The 2012 Senior Notes and the 2013 Senior Notes are effectively subordinated to secured obligations of the Company, including the 2012 Term Loan and the 2012 ABL Revolver and the 2010 Senior Notes, equal in right of payment to all existing and future unsecured obligations of the Company, and senior in right of payment to all existing and future subordinated obligations of the Company.

At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we may redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest, if any, on the 2013 Senior Notes plus an applicable "make-whole premium". On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof plus accrued and unpaid interest to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met.

The indentures governing the 2010 Senior Notes, the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At December 31, 2013, we were in compliance with the covenants under our long-term indebtedness.

- 15-

At December 31, 2013, we had an aggregate of $24.1 million of unamortized debt issuance costs and $3.5 million of unamortized debt discount. The total of which is comprised of $0.5 million related to the 2010 Senior Notes, $10.4 million related to the 2012 Senior Notes, $6.6 million related to the 2013 Senior Notes, $8.7 million related to the 2012 Term Loan, and $1.4 million related to the 2012 ABL Revolver.

During the nine months ended December 31, 2013, we borrowed a net amount of $4.5 million against the 2012 ABL Revolver.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	December 31, 2013			March 31, 2013
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year, commencing June 15, 2014. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	—
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term Loan bearing interest at the Company's option at either a base rate plus applicable margin with a floor of 2.00% or LIBOR with a floor of 1.00%, due on January 31, 2019.	297,500			445,000
2012 ABL Revolver bearing interest at the Company's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	37,500			33,000
2010 Senior Notes bearing interest at 8.25%, with interest payable on April 1 and October 1 of each year. The 2010 Senior Notes mature on April 1, 2018.	48,290			250,000
	1,033,290			978,000
Current portion of long-term debt	48,290			—
	985,000			978,000
Less: unamortized discount	(3,489		)	(7,100		)
Long-term debt, net of unamortized discount	$	981,511		$	970,900

As of December 31, 2013, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes, the 2012 Senior Notes, and the 2010 Senior Notes are as follows:



(In thousands)
Year Ending March 31,	Amount
2014 (remaining three months ending March 31, 2014)	$	48,290
2015	—
2016	—
2017	37,500
2018	—
Thereafter	947,500
	$	1,033,290


11.	Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

The Fair Value Measurements and Disclosures topic of the FASB ASC requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

- 16-

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2012 Term Loan, the 2013 Senior Notes, the 2012 Senior Notes, the 2010 Senior Notes and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At December 31, 2013 and March 31, 2013, we did not have any assets or liabilities measured in Level 1 or 3. During any of the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3.

At December 31, 2013 the carrying value and market value of our 2013 Senior Notes was $400.0 million and $403.0 million, respectively.

At December 31, 2013 and March 31, 2013, the carrying value of our 2012 Senior Notes was $250.0 million. The market value of our 2012 Senior Notes was $279.1 million and $281.9 million at December 31, 2013 and March 31, 2013, respectively.

At December 31, 2013 and March 31, 2013, the carrying value of the 2012 Term Loan was $297.5 million and $445.0 million, respectively. The market value of the 2012 Term Loan was $299.0 million and $451.1 million at December 31, 2013 and March 31, 2013, respectively.

At December 31, 2013 and March 31, 2013, the carrying value of our 2010 Senior Notes was $48.3 million and $250.0 million, respectively. The market value of our 2010 Senior Notes was $51.1 million and $271.9 million at December 31, 2013 and March 31, 2013, respectively.

At December 31, 2013, the carrying value and market value of the 2012 ABL Revolver was $37.5 million. At March 31, 2013, the carrying value and market value of the 2012 ABL Revolver was $33.0 million.


12.	Stockholders' Equity

The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.

Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through December 31, 2013.

Pursuant to the provisions of various employee restricted stock awards, we repurchased 2,549 shares and 13,275 shares of restricted common stock from our employees during the three and nine months ended December 31, 2013, respectively. During the three and nine months ended December 31, 2012, we did not repurchase any shares of restricted common stock from our employees pursuant to the provisions of the various employee restricted stock awards. The repurchases during the nine months ended December 31, 2013 were at an average price of $27.81. All of the repurchased shares have been recorded as treasury stock.


13.	Accumulated Other Comprehensive Loss

The table below presents accumulated other comprehensive loss (“AOCI”), which is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. As discussed in Note 1 above, ASU 2013-02 did not have a significant impact on our financial statements.

- 17-

AOCI consisted of the following at December 31, 2013 and March 31, 2013:



	December 31,			March 31,
(In thousands)	2013			2013
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(1,675	)	$	(104	)
Total accumulated other comprehensive loss, net of tax	$	(1,675	)	$	(104	)


14.	Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2013		2012		2013		2012
Numerator
Net income	$	3,130	$	12,257	$	56,614	$	46,156

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	51,806		50,686		51,498		50,465
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	639		837		738		820
Denominator for diluted earnings per share	52,445		51,523		52,236		51,285

Earnings per Common Share:
Basic net earnings per share	$	0.06	$	0.24	$	1.10	$	0.91

Diluted net earnings per share	$	0.06	$	0.24	$	1.08	$	0.90

For the three months ended December 31, 2013 and 2012, there were 0.2 million and less than 0.1 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2013 and 2012, there were 0.2 million and less than 0.1 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.


15.	Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for the grant of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During the three months and nine months ended December 31, 2013, pre-tax share-based compensation costs charged against income were $1.3 million and $3.8 million, respectively, and the related income tax benefit recognized was $0.4 million and $1.1 million, respectively. During the three and nine months ended December 31, 2012, pre-tax share-based compensation costs charged against income were $1.0 million and $3.0 million, respectively, and the related income tax benefit recognized was $0.3 million and $0.9 million, respectively.

- 18-

Restricted Shares and Restricted Stock Units

Restricted shares and restricted stock units granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals by the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted share and restricted stock unit awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.

On May 14, 2013, the Compensation Committee of our Board of Directors granted 113,637 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 55,637 restricted stock units vest in their entirety on the three-year anniversary of the date of grant, and 58,000 restricted stock units vest 33.3% per year over three years. On November 5, 2013, the Compensation Committee of our Board of Directors granted 6,000 restricted stock units to certain employees under the Plan, which will vest 33.3% per year over three years. On July 29, 2013, the Compensation Committee of the Board of Directors granted 7,004 restricted stock units to the independent members of the Board of Directors under the Plan.

The fair value of the restricted stock units is determined using the closing price of our common stock on the day of grant. The weighted-average grant-date fair value of restricted stock units granted during the nine months ended December 31, 2013 and 2012 was $30.19 and $13.59, respectively.

A summary of the Company's restricted shares and restricted stock units granted under the Plan is presented below:



Restricted Shares and Restricted Stock Units	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Nine months ended December 31, 2012:
Outstanding at March 31, 2012	363.4		$	9.92
Granted	128.9		13.59
Vested and issued	(27.0	)	7.16
Forfeited	(12.3	)	10.69
Outstanding at December 31, 2012	453.0		11.11
Vested at December 31, 2012	70.4		8.52

Nine months ended December 31, 2013:
Outstanding at March 31, 2013	421.3		$	11.01
Granted	126.6		30.19
Vested and issued	(59.7	)	8.42
Forfeited	(5.6	)	15.11
Outstanding at December 31, 2013	482.6		16.32
Vested at December 31, 2013	83.1		9.63

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived

- 19-

from management's estimates and consideration of information derived from the public filings of companies similar to us and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option. On May 14, 2013, the Compensation Committee of our Board of Directors granted stock options to acquire 227,672 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $29.94 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

The weighted-average grant-date fair value of the options granted during the nine months ended December 31, 2013 and 2012 was $13.94 and $6.03, respectively.



	Nine Months Ended December 31,
	2013			2012
Expected volatility	48.0		%	44.0		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.5
Risk-free rate	1.3		%	1.2		%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Nine months ended December 31, 2012:
Outstanding at March 31, 2012	1,745.4		$	8.44
Granted	444.9		13.36
Exercised	(708.5	)	7.71
Forfeited or expired	(17.4	)	11.21
Outstanding at December 31, 2012	1,464.4		10.26		7.7	$	11,330
Exercisable at December 31, 2012	332.4		9.99		6.8	2,248

Nine months ended December 31, 2013:
Outstanding at March 31, 2013	1,386.4		$	10.43
Granted	227.7		29.94
Exercised	(589.9	)	9.73
Forfeited or expired	(14.2	)	14.56
Outstanding at December 31, 2013	1,010.0		15.18		7.6	$	20,828
Exercisable at December 31, 2013	172.1		11.34		6.8	4,210

The aggregate intrinsic value of options exercised in the nine months ended December 31, 2013 was $13.7 million. The aggregate intrinsic value for options granted during the nine months ended December 31, 2013 was $1.3 million.

At December 31, 2013, there were $5.0 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 0.9 years. The total fair value of options and restricted shares vested during the nine months ended December 31, 2013 and 2012 was $3.2 million and $2.1 million, respectively. For the nine months ended December 31, 2013 and 2012, cash received from the exercise of stock options was $5.7 million and $5.4 million, respectively, and we realized $1.7 million and $9.3 million, respectively, in tax benefits for the tax deductions resulting from these option exercises. At December 31, 2013, there were 1.6 million shares available for issuance under the Plan.

- 20-


16.	Income Taxes

Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rate used in the calculation of income taxes was 25.2% and 38.9% for the three months ended December 31, 2013 and December 31, 2012, respectively. The effective tax rate used in the calculation of income taxes was 24.6% and 38.9% for the nine months ended December 31, 2013 and December 31, 2012, respectively. The decrease in the effective tax rate for the three months ended December 31, 2013 was primarily due to the impact of lower state income tax rates on the lower profitability of the Company due primarily to the loss on debt extinguishment. The decrease in the effective tax rate for the nine months ended December 31, 2013 was primarily due to a one-time benefit of $0.4 million and $8.9 million, respectively, to adjust our current and deferred tax balances for lower state income taxes. This benefit was primarily related to a recent law change in the state where we have our major distribution center to tax earnings attributed to in-state revenues only.

At December 31, 2013, a wholly-owned subsidiary had a net operating loss carryforward of approximately $1.0 million, which may be used to offset future taxable income of the consolidated group and which begins to expire in 2020. The net operating loss carryforward is subject to an annual limitation as to usage of approximately $0.2 million pursuant to Internal Revenue Code Section 382.

We experienced a net increase of $0.2 million in our uncertain tax liability during the nine months ended December 31, 2013. Therefore, the balance in our uncertain tax liability was $1.2 million and $1.0 million at December 31, 2013 and March 31, 2013, respectively. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

17. Commitments and Contingencies

We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition or results from operations.

Lease Commitments

We have operating leases for office facilities and equipment in New York and Wyoming, which expire at various dates through 2018. Due to the acquisition of the GSK Brands, we required additional office space and entered into a 5.5 year lease for a new office facility in New York, which began in the third quarter of fiscal 2013. In May 2012, we also entered into a three year lease for an office in Rogers, Arkansas. These amounts have been included in the schedule below.

The following summarizes future minimum lease payments for our operating leases as of December 31, 2013:



(In thousands)
Year Ending March 31,	Facilities		Equipment		Total
2014 (Remaining three months ending March 31, 2014)	$	459	$	35	$	494
2015	1,049		136		1,185
2016	994		135		1,129
2017	1,023		68		1,091
2018	1,044		—		1,044
Thereafter	—		—		—
	$	4,569	$	374	$	4,943

Rent expense for each of the three months ended December 31, 2013 and 2012 was $0.4 million and $0.3 million, respectively, while rent expense for each of the nine months ended December 31, 2013 and 2012 was $1.2 million and $0.9 million, respectively.

- 21-

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,	Amount
2014 (Remaining three months ending March 31, 2014)	$	281
2015	1,105
2016	1,074
2017	1,044
2018	1,013
Thereafter	1,542
	$	6,059


18.	Concentrations of Risk

Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and dollar and club stores. During the three and nine months ended December 31, 2013, approximately 41.1% and 41.7%, respectively, of our total revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2012, approximately 40.3% and 40.7%, respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 20.4% and 19.7%, respectively, of our gross revenues for the three and nine months ended December 31, 2013, and approximately 21.5% and 21.3%, respectively, of our gross revenues for the three and nine months ended December 31, 2012. At December 31, 2013, approximately 20.2% of accounts receivable were owed by the same customer.

We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability.

At December 31, 2013, we had relationships with 58 third-party manufacturers pertaining to our domestic operations. Of those, we had long-term contracts with 21 manufacturers that produced items that accounted for approximately 86.3% of gross sales for the nine months ended December 31, 2013. At December 31, 2012, we had relationships with 62 third-party manufacturers. Of those, we had long-term contracts with 24 manufacturers that produced items that accounted for approximately 77.1% of gross sales for the nine months ended December 31, 2012. The fact that we do not have long-term contracts with certain manufacturers means they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition and results from operations.

- 22-

19. Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current operating and reportable segments consist of (i) OTC Healthcare and (ii) Household Cleaning. There were no inter-segment sales or transfers during any of the periods presented. We evaluate the performance of our operating segments and allocate resources to them based primarily on contribution margin.

The tables below summarize information about our operating and reportable segments.



	Three Months Ended December 31, 2013						Nine Months Ended December 31, 2013
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated		OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	125,448	$	19,606	$	145,054	$	390,670	$	63,489	$	454,159
Other revenues	150		1,008		1,158		462		3,004		3,466
Total revenues	125,598		20,614		146,212		391,132		66,493		457,625
Cost of sales	49,042		15,361		64,403		149,378		48,236		197,614
Gross profit	76,556		5,253		81,809		241,754		18,257		260,011
Advertising and promotion	24,830		740		25,570		68,375		2,379		70,754
Contribution margin	$	51,726	$	4,513	56,239		$	173,379	$	15,878	189,257
Other operating expenses					15,781						45,596
Operating income					40,458						143,661
Other expense					36,272						68,616
Income before income taxes					4,186						75,045
Provision for income taxes					1,056						18,431
Net income					$	3,130					$	56,614



	Three Months Ended December 31, 2012						Nine Months Ended December 31, 2012
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated		OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	138,858	$	20,634	$	159,492	$	402,633	$	64,102	$	466,735
Other revenues	175		565		740		520		1,829		2,349
Total revenues	139,033		21,199		160,232		403,153		65,931		469,084
Cost of sales	59,381		15,854		75,235		160,249		49,689		209,938
Gross profit	79,652		5,345		84,997		242,904		16,242		259,146
Advertising and promotion	22,410		1,128		23,538		62,309		5,062		67,371
Contribution margin	$	57,242	$	4,217	61,459		$	180,595	$	11,180	191,775
Other operating expenses					14,737						50,064
Operating income					46,722						141,711
Other expense					26,661						66,169
Income before income taxes					20,061						75,542
Provision for income taxes					7,804						29,386
Net income					$	12,257					$	46,156

- 23-

The table below summarizes information about our revenues from similar product groups.



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2013		2012		2013		2012
Analgesics	$	25,903	$	27,946	$	84,634	$	81,727
Cough & Cold	34,330		37,424		89,548		94,197
Gastrointestinal	20,190		24,977		64,841		74,510
Eye & Ear Care	19,400		19,702		63,519		63,109
Dermatologicals	9,797		11,496		40,223		41,578
Oral Care	11,408		12,953		35,845		36,032
Other OTC	4,570		4,535		12,522		12,000
Total OTC Healthcare Segment	125,598		139,033		391,132		403,153
Household Cleaning Segment	20,614		21,199		66,493		65,931
Consolidated Total Revenues	$	146,212	$	160,232	$	457,625	$	469,084

During the three and nine months ended December 31, 2013, approximately 85.7% and 87.2%, respectively, of our sales were made to customers in the United States, while during the three and nine months ended December 31, 2012, approximately 89.1% and 89.9% , respectively, of our sales were made to customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three and nine months ended December 31, 2013, sales to Canada accounted for approximately 8.3% and 7.8%, respectively, of our total revenues, while during the three and nine months ended December 31, 2012 approximately 8.1% and 7.5%, respectively, of our total revenue was attributable to sales to Canada.

At December 31, 2013, substantially all of our long-term assets were located in the United States and have been allocated to the operating segments as follows:



(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	182,566	$	7,389	$	189,955

Intangible assets
Indefinite-lived	1,152,824		119,820		1,272,644
Finite-lived	96,508		26,603		123,111
	1,249,332		146,423		1,395,755
	$	1,431,898	$	153,812	$	1,585,710

- 24-

20. Condensed Consolidating Financial Statements

As described in Note 10, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, have fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes, including, without limitation, the obligation to pay principal and interest with respect to the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes. Although holders of the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes, 2012 Senior Notes or the 2010 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes, 2012 Senior Notes or the 2010 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of December 31, 2013 and March 31, 2013, Condensed Consolidating Income and Comprehensive Income Statements for the three and nine months ended December 31, 2013 and 2012, and Condensed Consolidating Statements of Cash Flows for the nine months ended December 31, 2013 and 2012. Such consolidating information includes separate columns for:

a) Prestige Brands Holdings, Inc., the parent,

b) Prestige Brands, Inc., the issuer,

c) Combined Subsidiary Guarantors,

d) Combined Non-Guarantor Subsidiaries, and

e) Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.

In the third quarter of fiscal 2014, the Company determined that it had incorrectly recorded certain intercompany transactions relating to the second quarter of fiscal 2014. This resulted in an understatement of equity in earnings of subsidiaries for Prestige Brands, Inc. (the "Issuer") of $48.1 million, an overstatement of $0.6 million for Prestige Brands Holdings, Inc. (the "Parent")and a net understatement of equity in earnings of subsidiaries for the eliminations of $47.5 million for each of the three and six month periods ended September 30, 2013. These items also resulted in corresponding adjustments to the Investments in subsidiaries on the balance sheet as of September 30, 2013 and adjustments to net income (loss) and equity in income of subsidiaries in the statement of cash flows, although net cash provided by operating activities for the six months ended September 30, 2013 remained unchanged. Revisions were also made to increase the cumulative translation adjustment of the Issuer and subsidiary guarantors by approximately $1 million each, with corresponding adjustments to the Investment in subsidiaries and stockholders' equity balances.

The Company assessed the materiality of these items on the previously issued interim financial statements in accordance with SEC Staff Accounting Bulletin No. 99 and No. 108, and concluded that the revisions were not material to the consolidated financial statements. The Company will disclose the impact of the revisions on previously reported amounts and accordingly revised the Condensed Consolidating Financial Statements for comparative periods in its future filings. There were no changes to any of the Company's Consolidated Financial Statements.

- 25-

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,689		$	113,685		$	7,502		$	(1,822	)	$	145,054
Other revenues	—			75			1,160			10			(87		)	1,158
Total revenues	—			25,764			114,845			7,512			(1,909		)	146,212

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,361			53,750			2,325			(1,033		)	64,403
Gross profit	—			16,403			61,095			5,187			(876		)	81,809

Operating Expenses
Advertising and promotion	—			2,066			21,359			2,145			—			25,570
General and administrative	165			2,132			8,967			873			—			12,137
Depreciation and amortization	983			149			2,440			72			—			3,644
Total operating expenses	1,148			4,347			32,766			3,090			—			41,351
Operating income (loss)	(1,148		)	12,056			28,329			2,097			(876		)	40,458

Other (income) expense
Interest (income)	(12,305		)	(14,437		)	(731		)	(6		)	27,463			(16		)
Interest expense	8,671			21,276			18,061			731			(27,463		)	21,276
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(1,148		)	(6,845		)	(999		)	—			8,992			—
Total other (income) expense	(4,782		)	15,006			16,331			725			8,992			36,272
Income before income taxes	3,634			(2,950		)	11,998			1,372			(9,868		)	4,186
Provision (benefit) for income taxes	504			(2,541		)	2,720			373			—			1,056
Net income (loss)	$	3,130		$	(409	)	$	9,278		$	999		$	(9,868	)	$	3,130

Comprehensive income, net of tax:
Currency translation adjustments	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Total other comprehensive income (loss)	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Comprehensive income (loss)	$	436		$	(3,103	)	$	6,584		$	(1,695	)	$	(1,786	)	$	436

- 26-

Condensed Consolidating Statements of Income and Comprehensive Income

Nine Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	75,339		$	364,468		$	16,174		$	(1,822	)	$	454,159
Other revenues	—			210			3,454			1,112			(1,310		)	3,466
Total revenues	—			75,549			367,922			17,286			(3,132		)	457,625

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			28,157			165,252			6,461			(2,256		)	197,614
Gross profit	—			47,392			202,670			10,825			(876		)	260,011

Operating Expenses
Advertising and promotion	—			9,254			57,751			3,749			—			70,754
General and administrative	2,555			5,256			25,782			1,797			—			35,390
Depreciation and amortization	2,017			434			7,625			130			—			10,206
Total operating expenses	4,572			14,944			91,158			5,676			—			116,350
Operating income (loss)	(4,572		)	32,448			111,512			5,149			(876		)	143,661

Other (income) expense
Interest (income)	(37,296		)	(42,765		)	(1,441		)	(30		)	81,488			(44		)
Interest expense	25,965			53,648			54,082			1,441			(81,488		)	53,648
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Total other (income) expense	(62,678		)	(16,102		)	49,774			1,411			96,211			68,616
Income before income taxes	58,106			48,550			61,738			3,738			(97,087		)	75,045
Provision (benefit) for income taxes	1,492			1,609			14,459			871			—			18,431
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614

Comprehensive income, net of tax:
Currency translation adjustments	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Total other comprehensive income (loss)	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Comprehensive income (loss)	$	55,043		$	45,370		$	45,708		$	1,296		$	(92,374	)	$	55,043

- 27-

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,345		$	132,881		$	1,266		$	—		$	159,492
Other revenues	—			79			724			276			(339		)	740
Total revenues	—			25,424			133,605			1,542			(339		)	160,232

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,877			65,172			525			(339		)	75,235
Gross profit	—			15,547			68,433			1,017			—			84,997

Operating Expenses
Advertising and promotion	—			3,032			19,997			509			—			23,538
General and administrative	952			1,585			8,734			107			—			11,378
Depreciation and amortization	549			140			2,658			12			—			3,359
Total operating expenses	1,501			4,757			31,389			628			—			38,275
Operating income (loss)	(1,501		)	10,790			37,044			389			—			46,722

Other (income) expense
Interest (income)	33			(41,552		)	162			(62		)	41,415			(4		)
Interest expense	8,735			35,394			23,951			—			(41,415		)	26,665
Equity in (income) loss of subsidiaries	(18,531		)	(8,407		)	(393		)	—			27,331			—
Total other (income) expense	(9,763		)	(14,565		)	23,720			(62		)	27,331			26,661
Income before income taxes	8,262			25,355			13,324			451			(27,331		)	20,061
Provision (benefit) for income taxes	(3,995		)	6,593			5,030			176			—			7,804
Net income	$	12,257		$	18,762		$	8,294		$	275		$	(27,331	)	$	12,257

Comprehensive income, net of tax:
Currency translation adjustments	(1		)	(1		)	(1		)	(1		)	3			(1		)
Total other comprehensive income	(1		)	(1		)	(1		)	(1		)	3			(1		)
Comprehensive income	$	12,256		$	18,761		$	8,293		$	274		$	(27,328	)	$	12,256

- 28-

Condensed Consolidating Statements of Income and Comprehensive Income

Nine Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	75,294		$	387,815		$	3,626		$	—		$	466,735
Other revenues	—			220			2,310			1,270			(1,451		)	2,349
Total revenues	—			75,514			390,125			4,896			(1,451		)	469,084

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			28,493			181,382			1,514			(1,451		)	209,938
Gross profit	—			47,021			208,743			3,382			—			259,146

Operating Expenses
Advertising and promotion	—			8,917			57,326			1,128			—			67,371
General and administrative	3,676			5,020			30,802			616			—			40,114
Depreciation and amortization	818			420			8,667			45			—			9,950
Total operating expenses	4,494			14,357			96,795			1,789			—			117,435
Operating income (loss)	(4,494		)	32,664			111,948			1,593			—			141,711

Other (income) expense
Interest (income)	(24,337		)	(63,573		)	162			(163		)	87,902			(9		)
Interest expense	26,147			92,320			35,613			—			(87,902		)	66,178
Equity in (income) loss of subsidiaries	(50,008		)	(49,280		)	(1,306		)	—			100,594			—
Total other (income) expense	(48,198		)	(20,533		)	34,469			(163		)	100,594			66,169
Income before income taxes	43,704			53,197			77,479			1,756			(100,594		)	75,542
Provision (benefit) for income taxes	(2,452		)	1,524			29,631			683			—			29,386
Net income	$	46,156		$	51,673		$	47,848		$	1,073		$	(100,594	)	$	46,156

Comprehensive income, net of tax:
Currency translation adjustments	23			23			23			23			(69		)	23
Total other comprehensive income	23			23			23			23			(69		)	23
Comprehensive income	$	46,179		$	51,696		$	47,871		$	1,096		$	(100,663	)	$	46,179

- 29-

Condensed Consolidating Balance Sheet

December 31, 2013




(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	90,647		$	—		$	—		$	3,706		$	—		$	94,353
Accounts receivable, net	127			14,349			47,631			4,081			—			66,188
Inventories	—			14,660			46,020			4,994			(876		)	64,798
Deferred income tax assets	251			917			5,668			—			—			6,836
Prepaid expenses and other current assets	8,148			66			3,313			799			—			12,326
Total current assets	99,173			29,992			102,632			13,580			(876		)	244,501

Property and equipment, net	9,905			125			229			269			—			10,528
Goodwill	—			66,007			101,540			22,408			—			189,955
Intangible assets, net	—			192,995			1,172,004			30,756			—			1,395,755
Other long-term assets	—			24,107			—			—			—			24,107
Intercompany receivable	596,369			1,919,068			588,046			9,501			(3,112,984		)	—
Investment in subsidiary	1,536,312			735,694			8,259			—			(2,280,265		)	—
Total Assets	$	2,241,759		$	2,967,988		$	1,972,710		$	76,514		$	(5,394,125	)	$	1,864,846

Liabilities and Stockholders' Equity
Current liabilities
Current portion of long-term debt	$	—		$	48,290		$	—		$	—		$	—		$	48,290
Accounts payable	3,063			11,641			34,320			2,523			—			51,547
Accrued interest payable	—			10,781			—			—			—			10,781
Other accrued liabilities	6,144			3,299			10,249			3,753			—			23,445
Total current liabilities	9,207			74,011			44,569			6,276			—			134,063

Long-term debt
Principal amount	—			985,000			—			—			—			985,000
Less unamortized discount	—			(3,489		)	—			—			—			(3,489		)
Long-term debt, net of unamortized discount	—			981,511			—			—			—			981,511

Deferred income tax liabilities	—			55,316			149,652			68			—			205,036
Long term liabilities	—			—			—			302			—			302
Intercompany payable	1,688,618			394,359			992,745			37,262			(3,112,984		)	—
Total Liabilities	1,697,825			1,505,197			1,186,966			43,908			(3,112,984		)	1,320,912

Stockholders' Equity
Preferred share rights	283			—			—			—			—			283
Common stock	520			—			—			—			—			520
Additional paid-in capital	412,910			1,337,706			658,799			23,815			(2,020,320		)	412,910
Treasury stock, at cost - 194 shares	(965		)	—			—			—			—			(965		)
Accumulated other comprehensive income, net of tax	(1,675		)	(1,675		)	(1,675		)	(1,675		)	5,025			(1,675		)
Retained earnings (accumulated deficit)	132,861			126,760			128,620			10,466			(265,846		)	132,861
Total Stockholders' Equity	543,934			1,462,791			785,744			32,606			(2,281,141		)	543,934
Total Liabilities and Stockholders' Equity	$	2,241,759		$	2,967,988		$	1,972,710		$	76,514		$	(5,394,125	)	$	1,864,846

- 30-

Condensed Consolidating Balance Sheet

March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	14,720		$	—		$	—	$	950		$	—		$	15,670
Accounts receivable, net	21			13,875			58,345		812			—			73,053
Inventories	—			11,164			48,474		563			—			60,201
Deferred income tax assets	218			855			5,276		—			—			6,349
Prepaid expenses and other current assets	4,942			93			3,609		256			—			8,900
Total current assets	19,901			25,987			115,704		2,581			—			164,173

Property and equipment, net	9,609			34			253		—			—			9,896
Goodwill	—			66,007			101,539		—			—			167,546
Intangible assets, net	—			193,396			1,179,524		320			—			1,373,240
Other long-term assets	—			24,944			—		—			—			24,944
Intercompany receivable	653,049			1,911,573			415,587		7,316			(2,987,525		)	—
Investment in subsidiary	1,429,775			638,611			7,067		—			(2,075,453		)	—
Total Assets	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,601		$	10,600		$	37,695	$	480		$	—		$	51,376
Accrued interest payable	—			13,894			—		—			—			13,894
Other accrued liabilities	12,694			1,684			16,107		913			—			31,398
Total current liabilities	15,295			26,178			53,802		1,393			—			96,668

Long-term debt
Principal amount	—			978,000			—		—			—			978,000
Less unamortized discount	—			(7,100		)	—		—			—			(7,100		)
Long-term debt, net of unamortized discount	—			970,900			—		—			—			970,900

Deferred income tax liabilities	—			55,291			138,924		73			—			194,288
Intercompany payable	1,619,096			447,419			920,865		145			(2,987,525		)	—
Total Liabilities	1,634,391			1,499,788			1,113,591		1,611			(2,987,525		)	1,261,856

Stockholders' Equity
Preferred share rights	283			—			—		—			—			283
Common stock	513			—			—		—			—			513
Additional paid-in capital	401,691			1,280,945			624,742		1,111			(1,906,798		)	401,691
Treasury stock, at cost - 181 shares	(687		)	—			—		—			—			(687		)
Accumulated other comprehensive loss, net of tax	(104		)	—			—		(104		)	104			(104		)
Retained earnings (accumulated deficit)	76,247			79,819			81,341		7,599			(168,759		)	76,247
Total Stockholders' Equity	477,943			1,360,764			706,083		8,606			(2,075,453		)	477,943
Total Liabilities and Stockholders' Equity	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

- 31-

Condensed Consolidating Statement of Cash Flows

Nine Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,017			434			7,624			134			—			10,209
Deferred income taxes	(33		)	(37		)	10,336			(5		)	—			10,261
Amortization of deferred financing costs	—			6,023			—			—			—			6,023
Stock-based compensation costs	3,763			—			—			—			—			3,763
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Premium payment on 2010 Senior Notes Tendered	—			(12,768		)	—			—			—			(12,768		)
Amortization of debt discount	—			3,115			—			—			—			3,115
Gain on sale of assets	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(106		)	(474		)	10,714			(1,639		)	—			8,495
Inventories	—			(3,496		)	2,454			(2,096		)	876			(2,262		)
Prepaid expenses and other current assets	(3,206		)	27			296			100			—			(2,783		)
Accounts payable	462			1,041			(3,375		)	587			—			(1,285		)
Accrued liabilities	(6,550		)	(1,498		)	(5,858		)	375			—			(13,531		)
Net cash provided by operating activities	1,614			12,323			66,600			323			—			80,860

Investing Activities
Purchases of property and equipment	(2,555		)	—			—			(103		)	—			(2,658		)
Proceeds from the sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash provided by (used in) investing activities	(2,555		)	(55,215		)	3			(103		)	—			(57,870		)

Financing Activities
Proceeds from the issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Payment of 2010 Senior Notes	—			(201,710		)	—			—			—			(201,710		)
Repayments of long-term debt	—			(147,500		)	—			—			—			(147,500		)
Repayments under revolving credit agreement	—			(45,500		)	—			—			—			(45,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(6,933		)	—			—			—			(6,933		)
Proceeds from exercise of stock options	5,738			—			—			—			—			5,738
Excess tax benefits from share-based awards	1,725			—			—			—			—			1,725
Shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	69,683			(5,465		)	(66,603		)	2,385			—			—
Net cash provided by (used in) financing activities	76,868			42,892			(66,603		)	2,385			—			55,542

Effect of exchange rate changes on cash and cash equivalents	—			—			—			151			—			151
Increase in cash and cash equivalents	75,927			—			—			2,756			—			78,683
Cash - beginning of period	14,720			—			—			950			—			15,670
Cash - end of period	$	90,647		$	—		$	—		$	3,706		$	—		$	94,353

- 32-

Condensed Consolidating Statement of Cash Flows

Nine Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	46,156		$	51,673		$	47,848		$	1,073		$	(100,594	)	$	46,156
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	818			420			8,667			45			—			9,950
Deferred income taxes	143			44			15,796			(4		)	—			15,979
Amortization of deferred financing costs	—			8,220			—			—			—			8,220
Stock-based compensation costs	2,965			—			—			—			—			2,965
Lease termination costs	975			—			—			—			—			975
Amortization of debt discount	—			3,892			—			—			—			3,892
Loss on disposal of equipment	30			—			21			—			—			51
Equity in income of subsidiaries	(50,008		)	(49,280		)	(1,306		)	—			100,594			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(115		)	285			(13,474		)	(214		)	—			(13,518		)
Inventories	—			(1,242		)	(2,104		)	(5		)	—			(3,351		)
Prepaid expenses and other current assets	6,446			(369		)	(627		)	351			—			5,801
Accounts payable	(3,347		)	2,488			14,095			889			—			14,125
Accrued liabilities	(1,071		)	529			9,830			343			—			9,631
Net cash provided by (used in) operating activities	2,992			16,660			78,746			2,478			—			100,876

Investing Activities
Purchases of property and equipment	(8,922		)	—			—			—			—			(8,922		)
Proceeds from sale of property and equipment	—			—			15			—			—			15
Proceeds from the sale of the Phazyme brand	—			—			21,700			—			—			21,700
Acquisition of GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash (used in) provided by investing activities	(9,148		)	—			21,715			—			—			12,567

Financing Activities
Repayment of long-term debt	—			(167,500		)	—			—			—			(167,500		)
Repayments under revolving credit agreement	—			(8,000		)	—			—			—			(8,000		)
Borrowings under revolving credit agreement	—			48,000			—			—			—			48,000
Proceeds from exercise of stock options	5,460			—			—			—			—			5,460
Intercompany activity, net	(8,647		)	110,840			(100,461		)	(1,732		)	—			—
Net cash used in financing activities	(3,187		)	(16,660		)	(100,461		)	(1,732		)	—			(122,040		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			13			—			13
(Decrease) increase in cash and cash equivalents	(9,343		)	—			—			759			—			(8,584		)
Cash - beginning of period	18,221			—			—			794			—			19,015
Cash - end of period	$	8,878		$	—		$	—		$	1,553		$	—		$	10,431

- 33-

21. Subsequent Events

Redemption of the 2010 Senior Notes:

On December 17, 2013, we offered to redeem the 2010 Senior Notes at a premium of 6.33%, of which $201.7 million were redeemed on such date. The remaining $48.3 million were redeemed on January 16, 2014. As a result, during the quarter ended December 31, 2013, we recorded a $15.0 million loss on the early extinguishment of debt relating to the $201.7 million 2010 Senior Notes redeemed and will record an additional loss of approximately $3.3 million on the remaining $48.3 million tendered on January 16, 2014.

Product Supply Disruption:

One of the Company’s suppliers, which packages products accounting for approximately 8% of the Company’s sales, temporarily stopped production in mid-January and has not indicated when production will resume. We are in the process of qualifying alternative sources of supply and, until production resumes, will be allocating safety stock inventories. Until the supplier resumes production or alternative sources of supply are qualified, the Company may be unable to supply these products to its customers. We do not expect this supply interruption will have a material adverse effect in the fourth quarter of fiscal 2014, however, if unresolved, it could have a materially adverse effect on our business and results of operations in future periods.

- 34-


ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with the Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2013. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013, as well as those described in Part II, Item 1A., "Risk Factors" in this Quarterly Report on Form 10-Q and in future reports filed with the Securities and Exchange Commission (the "SEC").

See also “Cautionary Statement Regarding Forward-Looking Statements” on page 54 of this Quarterly Report on Form 10-Q.

General

We are engaged in the marketing, sales and distribution of brand name over-the-counter ("OTC") healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, club, convenience, and dollar stores in the United States and Canada and in certain other international markets. We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to grow our presence in these categories and, as a result, grow our sales and profits.

We have grown our product portfolio both organically and through acquisitions. We develop our core brands by investing in new product lines, brand extensions and providing advertising support. Acquisitions of OTC brands have also been an important part of our growth strategy. We have acquired well-recognized brands from consumer products and pharmaceutical companies. While many of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, most were considered “non-core” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created significant opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network. This is achieved through increased spending on advertising and promotional support, new sales and marketing strategies, improved packaging and formulations and innovative development of brand extensions.

Acquisitions and Divestitures

Acquisition of Care Pharmaceuticals Pty Ltd.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also carries a line of brands for children including Little Allergies, Little Eyes, and Little Cough. The brands acquired are complementary to our existing OTC Healthcare portfolio.

This acquisition was accounted for in accordance with the Business Combinations topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

- 35-



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,103

Accounts payable	1,537
Accrued expenses	2,505
Other long term liabilities	300
Total liabilities assumed	4,342

Net assets acquired	$	56,761

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

Sale of the Phazyme Brand

On October 31, 2012, we divested the Phazyme gas treatment brand, which was a non-core OTC brand that we acquired from GSK in January 2012. We received $21.7 million from the divestiture on October 31, 2012 and the remaining $0.6 million on January 4, 2013. The proceeds were used to repay debt. No significant gain or loss was recorded as a result of the sale.

Concurrent with the completion of the sale of the Phazyme brand, we entered into a Transitional Services Agreement with the buyer (the “Phazyme TSA”), whereby we agreed to provide the buyer with various services, including: marketing, operations, finance and other services, from the date of the acquisition primarily through January 31, 2013, with an option for additional support for the Canadian portion of that business through October 31, 2013, at the buyer's discretion. All Phazyme United States TSA services ended, as agreed, on January 31, 2013. The buyer elected to extend the Canadian portion of the TSA services on a month to month basis and terminated the support on October 31, 2013.

The following table presents the assets sold at October 31, 2012 related to the Phazyme brand:



(In thousands)	October 31, 2012
Components of assets sold:
Inventory	$	220
Prepaid expenses	100
Trade names	15,604
Goodwill	6,382

- 36-

Three Months Ended December 31, 2013 compared to the Three Months Ended December 31, 2012

Revenues



	Three Months Ended December 31,
Revenues	2013		%	2012		%	Increase (Decrease)			%
Analgesics	$	25,903	17.7	$	27,946	17.4	$	(2,043	)	(7.3	)
Cough & Cold	34,330		23.5	37,424		23.4	(3,094		)	(8.3	)
Gastrointestinal	20,190		13.8	24,977		15.6	(4,787		)	(19.2	)
Eye & Ear Care	19,400		13.3	19,702		12.3	(302		)	(1.5	)
Dermatologicals	9,797		6.7	11,496		7.2	(1,699		)	(14.8	)
Oral Care	11,408		7.8	12,953		8.1	(1,545		)	(11.9	)
Other OTC	4,570		3.1	4,535		2.8	35			0.8
Total OTC Healthcare Revenues	125,598		85.9	139,033		86.8	(13,435		)	(9.7	)
Household Cleaning	20,614		14.1	21,199		13.2	(585		)	(2.8	)
Consolidated Total Revenues	$	146,212	100.0	$	160,232	100.0	$	(14,020	)	(8.7	)

Revenues for the three months ended December 31, 2013 were $146.2 million, a decrease of $14.0 million, or 8.7%, versus the three months ended December 31, 2012. The decrease reflects the effects of the return to the market of competitive products that had been recalled and lower cough cold incidence levels. In addition, we estimate an approximate $10.0 million impact to sales resulting from reduced inventory levels at the end of the quarter, largely in the mass customer channel. Revenues from customers outside of North America, which represent 6.0% of total revenues for the quarter ended December 31, 2013, increased by $4.4 million, or 99.1%, during the three months ended December 31, 2013 compared to the three months ended December 31, 2012. The increase in international sales was primarily attributed to inclusion of the acquisition of Care Pharma.

OTC Healthcare Segment

Revenues for the OTC Healthcare segment decreased $13.4 million, or 9.7%, during the three months ended December 31, 2013 versus the three months ended December 31, 2012. This decrease was primarily due to declining revenues in the gastrointestinal, cough and cold, and analgesics product groups and the retailer inventory reductions. The decrease in the gastrointestinal group was caused primarily by decreases in revenues for both the Beano and Gaviscon brands. Beano revenues declined due to consumer shifts to probiotics and the expansion of private label products in the mass channel. Gaviscon was impacted by supply chain issues incurred last year which caused a shift in the timing of sales due to limited supply availability. The decrease in the cough and cold product group was due primarily to the decrease in revenues for the Pediacare brand, resulting from increased competition from products that had previously been recalled and a weak cough and cold season. The decrease in Pediacare was offset partly by the inclusion of the Fess line of cold/allergy and saline nasal health products. The decrease in the analgesics product group was due largely to the decrease in revenues for the Goody’s brand, which resulted from a change in the timing of promotional activity.

Household Cleaning Segment

Revenues for the Household Cleaning segment decreased by $0.6 million, or 2.8%, during the three months ended December 31, 2013 versus the three months ended December 31, 2012. The slight decline was attributed to an unfavorable product mix relative to the Spic and Span brand.

Cost of Sales



	Three Months Ended December 31,
Cost of Sales	2013		%	2012		%	Increase (Decrease)			%
OTC Healthcare	$	49,042	39.0	$	59,381	42.7	$	(10,339	)	(17.4	)
Household Cleaning	15,361		74.5	15,854		74.8	(493		)	(3.1	)
	$	64,403	44.0	$	75,235	47.0	$	(10,832	)	(14.4	)

Cost of sales decreased $10.8 million, or 14.4% during the three months ended December 31, 2013 versus the three months ended December 31, 2012. As a percentage of total revenue, cost of sales decreased to 44.0% in the three months ended December 31, 2013 from 47.0% in the three months ended December 31, 2012. The decrease in cost of sales as a percentage of revenues was

- 37-

primarily due to reductions in product costs attributed to sourcing activities, and a favorable product mix relative to the acquisition of Care Pharma brands.

OTC Healthcare Segment

Cost of sales for the OTC Healthcare segment decreased $10.3 million, or 17.4%, during the three months ended December 31, 2013 versus the three months ended December 31, 2012. As a percentage of OTC Healthcare revenues, cost of sales in the OTC Healthcare segment decreased to 39.0% in the months ended December 31, 2013 from 42.7% during the three months ended December 31, 2012. The decrease in cost of sales as a percentage of revenues was primarily due to reductions in product costs, attributed to sourcing activities, and a favorable product mix relative to the acquisition of Care Pharma brands.

Household Cleaning Segment

Cost of sales for the Household Cleaning segment decreased $0.5 million, or 3.1%, during the three months ended December 31, 2013 versus the three months ended December 31, 2012. As a percentage of Household Cleaning revenues, cost of sales decreased to 74.5% during the three months ended December 31, 2013 from 74.8% during the three months ended December 31, 2012. The decrease in the cost of sales as a percentage of revenues was the result of lower sales promotional spending and reductions in product costs due to sourcing activities.

Gross Profit



	Three Months Ended December 31,
Gross Profit	2013		%	2012		%	Increase (Decrease)			%
OTC Healthcare	$	76,556	61.0	$	79,652	57.3	$	(3,096	)	(3.9	)
Household Cleaning	5,253		25.5	5,345		25.2	(92		)	(1.7	)
	$	81,809	56.0	$	84,997	53.0	$	(3,188	)	(3.8	)

Gross profit for the three months ended December 31, 2013 decreased $3.2 million, or 3.8%, when compared with the three months ended December 31, 2012. As a percentage of total revenues, gross profit increased to 56.0% in the three months ended December 31, 2013 from 53.0% in the three months ended December 31, 2012. The increase in gross profit percentage was primarily due to reductions in product costs, attributed to sourcing activities, and a favorable product mix relative to the acquired Care Pharma brands.

OTC Healthcare Segment

Gross profit for the OTC Healthcare segment decreased $3.1 million, or 3.9%, during the three months ended December 31, 2013 versus the three months ended December 31, 2012. As a percentage of OTC Healthcare revenues, gross profit increased to 61.0% during the three months ended December 31, 2013 from 57.3% during the three months ended December 31, 2012. The increase in gross profit was primarily the result of the acquisition of Care Pharma products and the reduction of product costs due to sourcing activities.

Household Cleaning Segment

Gross profit for the Household Cleaning segment remained at $5.3 million during the three months ended December 31, 2013 and 2012. As a percentage of Household Cleaning revenue, gross profit increased to 25.5% during the three months ended December 31, 2013 from 25.2% during the three months ended December 31, 2012.

Contribution Margin



	Three Months Ended December 31,
Contribution Margin	2013		%	2012		%	Increase (Decrease)			%
OTC Healthcare	$	51,726	41.2	$	57,242	41.2	$	(5,516	)	(9.6	)
Household Cleaning	4,513		21.9	4,217		19.9	296			7.0
	$	56,239	38.5	$	61,459	38.4	$	(5,220	)	(8.5	)

Contribution margin, a non-GAAP financial measure used as a primary measure for evaluating segment performance, which is defined as gross profit less advertising and promotional expenses, decreased $5.2 million, or 8.5%, during the three months ended December 31, 2013 versus the three months ended December 31, 2012. The contribution margin decrease was primarily the result

- 38-

of lower sales volumes and slightly higher advertising and promotional spending partially offset by the Care Pharma acquisition and the higher gross profit percentage discussed above.

OTC Healthcare Segment

Contribution margin for the OTC Healthcare segment decreased $5.5 million, or 9.6%, during the three months ended December 31, 2013 versus the three months ended December 31, 2012. The contribution margin decline was primarily the result of the effects of lower sales volumes and slightly higher advertising and promotional spending partially offset by the higher gross profit percentage. Advertising and promotional spending increased $2.4 million, or 10.8%, due primarily to BC and Goody's new product launches.

Household Cleaning Segment

Contribution margin for the Household Cleaning segment increased $0.3 million, or 7.0%, during the three months ended December 31, 2013 versus the three months ended December 31, 2012. The contribution margin increase was the result of lower advertising and promotional spending.

General and Administrative

General and administrative expenses were $12.1 million for the three months ended December 31, 2013 versus $11.4 million for the three months ended December 31, 2012. The increase in general and administrative expenses was primarily due to an increase in salaries and benefits of $1.6 million, increased stock-based compensation of $0.3 million, and higher technology costs of $0.1 million incurred due to a new enterprise resource planning ("ERP") system implementation This increase was partially offset by a reduction of bonuses of $1.3 million primarily related to lower payments against our prior year end bonus accruals, decreased costs in business development and consulting costs of $0.3 million, and $0.1 million of costs associated with our office and warehouse relocations incurred in the prior year period.

Depreciation and Amortization

Depreciation and amortization expense was $3.6 million for the three months ended December 31, 2013 versus $3.4 million for the three months ended December 31, 2012. The increase in depreciation and amortization expense was due to the implementation of a new ERP system.

Interest Expense

Net interest expense was $21.3 million during the three months ended December 31, 2013 versus $26.7 million during the three months ended December 31, 2012. The decrease in interest expense was primarily the result of a lower level of indebtedness outstanding resulting from significant payments made on our 2012 Term Loan in 2013, as well as reduced borrowing rates primarily resulting from the amendment of our 2012 Term Loan completed in February 2013. The average cost of borrowing decreased to 8.5% for the three months ended December 31, 2013 from 10.2% for the three months ended December 31, 2012, which is attributed to the refinancing of debt in February 2013. The average indebtedness outstanding decreased from $1,047.3 million during the three months ended December 31, 2012 to $994.4 million during the three months ended December 31, 2013. The decrease in average indebtedness outstanding is the result of the significant payments made on the 2012 Term Loan, which resulted in lower outstanding debt.

Income Taxes

The provision for income taxes during the three months ended December 31, 2013 was $1.1 million versus $7.8 million during the three months ended December 31, 2012. The effective tax rate during the three months ended December 31, 2013 was 25.2% versus 38.9% during the three months ended December 31, 2012. The decrease in the effective tax rate was primarily due to the impact of lower state income tax rates on the lower profitability of the Company due primarily to the loss on debt extinguishment. This benefit was primarily related to a recent change in state law where we have our major distribution center that taxes earnings attributed to in-state revenues only. The estimated effective tax rate for the remaining quarter of the fiscal year ending March 31, 2014 is expected to be 36.2%.

- 39-

Nine Months Ended December 31, 2013 compared to the Nine Months Ended December 31, 2012

Revenues



	Nine Months Ended December 31,
Revenues	2013		%	2012		%	Increase (Decrease)			%
Analgesics	$	84,634	18.5	$	81,727	17.4	$	2,907		3.6
Cough & Cold	89,548		19.6	94,197		20.1	(4,649		)	(4.9	)
Gastrointestinal	64,841		14.2	74,510		15.9	(9,669		)	(13.0	)
Eye & Ear Care	63,519		13.9	63,109		13.5	410			0.6
Dermatologicals	40,223		8.8	41,578		8.9	(1,355		)	(3.3	)
Oral Care	35,845		7.8	36,032		7.7	(187		)	(0.5	)
Other OTC	12,522		2.7	12,000		2.6	522			4.4
Total OTC Healthcare Revenues	391,132		85.5	403,153		85.9	(12,021		)	(3.0	)
Household Cleaning	66,493		14.5	65,931		14.1	562			0.9
Consolidated Total Revenues	$	457,625	100.0	$	469,084	100.0	$	(11,459	)	(2.4	)

Revenues for the nine months ended December 31, 2013 were $457.6 million, a decrease of $11.5 million, or 2.4%, versus the nine months ended December 31, 2012. The decrease in revenues reflects the effects on revenue of increased competition from the introduction of new brands or brands that had previously been recalled, a weak cough and cold season, and the impact of the divestiture of Phazyme, which were offset partly by the acquisition of the Care Pharma products and the launch of new analgesics products. Revenues from customers outside of North America, which represent 5.0% of total revenues for the nine months ended December 31, 2013, increased by $10.8 million, or 90.0%, during the nine months ended December 31, 2013 compared to the nine months ended December 31, 2012. The increase in international sales was largely attributed to the inclusion of the acquired Care products.

OTC Healthcare Segment

Revenues for the OTC Healthcare segment decreased $12.0 million, or 3.0%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. This decrease was largely caused by declines in the gastrointestinal, cough and cold, and dermatological groups, offset by increased revenues in the analgesic group. Revenues for the gastrointestinal group decreased primarily due decreased revenues for both the Beano and Gaviscon brands as well as the effects of the divestiture of Phazyme. Beano revenues declined due to consumer shifts to probiotics and the expansion of private label products in the mass channel. Gaviscon was impacted by supply chain issues incurred last year which caused a shift in the timing of sales due to limited supply availability. The decrease in the cough and cold product group was due primarily to the decrease in revenues for the Pediacare brand, resulting from increased competition from products that had previously been recalled and a weak cough and cold season. The decrease in Pediacare was offset partly by the inclusion of the Fess line of cold/allergy and saline nasal health products. The decrease in the dermatological group was due largely to decreased revenues for the Compound W brand, which experienced an overall decline in the wart removal category. The increased revenue in the analgesic product group reflected new product launches for the BC and Goody's brands and the inclusion of the Painstop brand, one of the acquired Care Pharma products.

Household Cleaning Segment

Revenues for the Household Cleaning segment increased by $0.6 million, or 0.9%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012 due to increases in the Comet brand attributable to increased sales volumes and lower promotional spending.

Cost of Sales



	Nine Months Ended December 31,
Cost of Sales	2013		%	2012		%	Increase (Decrease)			%
OTC Healthcare	$	149,378	38.2	$	160,249	39.7	$	(10,871	)	(6.8	)
Household Cleaning	48,236		72.5	49,689		75.4	(1,453		)	(2.9	)
	$	197,614	43.2	$	209,938	44.8	$	(12,324	)	(5.9	)

- 40-

Cost of sales decreased $12.3 million, or 5.9%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. As a percentage of total revenue, cost of sales decreased to 43.2% in the nine months ended December 31, 2013 from 44.8% in the nine months ended December 31, 2012. The decrease in cost of sales as a percentage of revenues was primarily due to reductions in product costs attributed to sourcing activities and a favorable product mix relative to the acquisition of Care Pharma, offset by the one-time adjustment for acquisition costs for the Care Pharma inventory.

OTC Healthcare Segment

Cost of sales for the OTC Healthcare segment decreased $10.9 million, or 6.8%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. As a percentage of OTC Healthcare revenues, cost of sales in the OTC Healthcare segment decreased to 38.2% during the nine months ended December 31, 2013 from 39.7% during the nine months ended December 31, 2012. The decrease in cost of sales as a percentage of revenues was primarily attributable to reductions in product costs due to sourcing activities and a favorable product mix relative to the acquisition of Care Pharma, offset by the one-time adjustment for acquisition costs for the Care Pharma inventory.

Household Cleaning Segment

Cost of sales for the Household Cleaning segment decreased $1.5 million, or 2.9%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. As a percentage of Household Cleaning revenues, cost of sales decreased to 72.5% during the nine months ended December 31, 2013 from 75.4% during the nine months ended December 31, 2012. The decrease in the cost of sales as a percentage of revenues was the result of lower sales promotional spending, which resulted in higher net revenue relative to product cost.

Gross Profit



	Nine Months Ended December 31,
Gross Profit	2013		%	2012		%	Increase (Decrease)			%
OTC Healthcare	$	241,754	61.8	$	242,904	60.3	$	(1,150	)	(0.5	)
Household Cleaning	18,257		27.5	16,242		24.6	2,015			12.4
	$	260,011	56.8	$	259,146	55.2	$	865		0.3

Gross profit for the nine months ended December 31, 2013 increased $0.9 million, or 0.3%, when compared with the nine months ended December 31, 2012. As a percentage of total revenues, gross profit increased to 56.8% during the nine months ended December 31, 2013 from 55.2% in the nine months ended December 31, 2012. The higher gross profit percentage was primarily the result of the decrease in promotion spending in the nine months ended December 31, 2013, resulting in a higher net revenue relative to product cost. The increase was also attributable to reductions in product costs due to sourcing activities and a favorable product mix relative to the acquisition of Care Pharma, offset by the one-time adjustment for acquisition costs for the Care Pharma inventory.

OTC Healthcare Segment

Gross profit for the OTC Healthcare segment decreased $1.2 million, or 0.5%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. As a percentage of OTC Healthcare revenues, gross profit increased to 61.8% during the nine months ended December 31, 2013 from 60.3% during the nine months ended December 31, 2012.

Household Cleaning Segment

Gross profit for the Household Cleaning segment increased by $2.0 million, or 12.4%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. As a percentage of Household Cleaning revenue, gross profit increased from 24.6% during the nine months ended December 31, 2012 to 27.5% during the nine months ended December 31, 2013. The increase in gross profit was primarily the result of the lower promotional spending, which resulted in higher net revenue relative to product cost.

- 41-

Contribution Margin



	Nine Months Ended December 31,
Contribution Margin	2013		%	2012		%	Increase (Decrease)			%
OTC Healthcare	$	173,379	44.3	$	180,595	44.8	$	(7,216	)	(4.0	)
Household Cleaning	15,878		23.9	11,180		17.0	4,698			42.0
	$	189,257	60.8	$	191,775	40.9	$	(2,518	)	(1.3	)

Contribution margin, a non-GAAP financial measure used as a primary measure for evaluating segment performance, which is defined as gross profit less advertising and promotional expenses, decreased $2.5 million, or 1.3%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. The contribution margin decrease was primarily the result of the lower sales volumes and higher advertising and promotional spending.

OTC Healthcare Segment

Contribution margin for the OTC Healthcare segment decreased $7.2 million, or 4.0%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. The contribution margin decrease was primarily the result of slightly higher advertising and promotional spending. Advertising and promotional spending increased $6.1 million, or 9.7%, due primarily to BC, Goody's, and Fiber Choice new product launches.

Household Cleaning Segment

Contribution margin for the Household Cleaning segment increased $4.7 million, or 42.0%, during the nine months ended December 31, 2013 versus the nine months ended December 31, 2012. The contribution margin increase was the result of the increased gross profit as a percentage of revenues and lower advertising and promotional spending.

General and Administrative

General and administrative expenses were $35.4 million for the nine months ended December 31, 2013 versus $40.1 million for the nine months ended December 31, 2012. The decrease in general and administrative expenses was primarily due to transition and integration costs of $4.1 million associated with the brands acquired from GSK incurred in the prior year period, a decrease in bonuses of $3.6 million primarily related to lower payments against our prior year end bonus accruals, a lease termination charge of $1.1 million associated with our office relocation and $0.7 million in warehouse relocation costs incurred in the prior year period, $0.5 million of fees related to an unsolicited proposal we received in the prior year period, and other business development and consulting costs in the prior year period. This decrease was partially offset by increased salaries and benefits of $3.8 million, increased stock based compensation of $0.8 million, increased corporate events and conventions of $0.4 million, higher technology costs of $0.5 million incurred due to a new ERP system implementation and $0.7 million of costs associated with the Care Pharma acquisition completed in July 2013.

Depreciation and Amortization

Depreciation and amortization expense was $10.2 million for the nine months ended December 31, 2013 versus $10.0 million for the nine months ended December 31, 2012. The increase in depreciation and amortization expense was due to the implementation of a new ERP system.

Interest Expense

Net interest expense was $53.6 million during the nine months ended December 31, 2013 versus $66.2 million during the nine months ended December 31, 2012. The decrease in interest expense was primarily the result of a lower level of indebtedness outstanding resulting from significant payments made on our 2012 Term Loan in 2013, as well as reduced borrowing rates primarily resulting from the amendment of our 2012 Term Loan competed in February 2013. The average cost of borrowing decreased to 7.3% for the nine months ended December 31, 2013 from 8.1% for the nine months ended December 31, 2012, which is attributed to refinancing of debt in February 2013. The average indebtedness outstanding decreased from $1,088.3 million during the nine months ended December 31, 2012 to $983.6 million during the nine months ended December 31, 2013. The decrease in the average indebtedness outstanding is the result of the significant payments made on the 2012 Term Loan, which resulted in lower outstanding debt.

- 42-

Income Taxes

The provision for income taxes during the nine months ended December 31, 2013 was $18.4 million versus $29.4 million during the nine months ended December 31, 2012. The effective tax rate during the nine months ended December 31, 2013 was 24.6% versus 38.9% during the nine months ended December 31, 2012. The decrease in the effective tax rate was primarily due to a one-time benefit of $8.9 million to adjust our current and deferred tax balances for lower state income taxes. This benefit was primarily related to a recent change in state law where we have our major distribution center that taxes earnings attributed to in-state revenues only. The estimated effective tax rate for the remaining quarter of the fiscal year ending March 31, 2014 is expected to be 36.2%.

Liquidity and Capital Resources

Liquidity

Our primary source of cash comes from our cash flow from operations. In the past, we have supplemented this source of cash with various debt facilities, primarily in connection with acquisitions. We have financed and expect to continue to finance our operations over the next twelve months, with a combination of borrowings and funds generated from operations. Our principal uses of cash are for operating expenses, debt service, acquisitions, working capital and capital expenditures.

We entered into a 5.5 year lease for a new office facility in New York, which began on October 15, 2012. The New York office lease provides for a six month rent deferral with monthly rent payments beginning in May 2013 of approximately $78,000 and escalating to approximately $87,000 in the last two years of the lease.

On March 24, 2010, we issued $150.0 million of senior notes that bear interest at 8.25% with a maturity date of April 1, 2018 (the "2010 Senior Notes"). In November 2010, we issued an additional $100.0 million of 2010 Senior Notes and borrowed an additional $115.0 million term loan under our former credit facility ("the 2010 Credit Facility").

On January 31, 2012, we issued $250.0 million of 8.125% senior notes with a maturity date of February 1, 2020 (the “2012 Senior Notes”) and also entered into a senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In September 2012, we utilized a portion of the accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $25.0 million to $75.0 million, and in June 2013, we further increased the amount of our borrowing capacity under the 2012 ABL Revolver by $20.0 million to $95.0 million and reduced our borrowing rate by 0.25%. We used the net proceeds from the 2012 Senior Notes offering, together with the borrowings under the 2012 Term Loan, to finance the acquisition of the GSK Brands, to repay amounts borrowed under the 2010 Credit Facility, to pay fees and expenses incurred in connection with these transactions and for general corporate purposes.

On February 21, 2013, we entered into Amendment No. 1 (the "Amendment") to the 2012 Term Loan. The Amendment provides for the refinancing of all of our existing Term B Loans with new Term B-1 Loans. The interest rate on the Term B-1 Loans is based, at our option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin. The new Term B-1 Loans will mature on the same date as the Term B Loans' original maturity date. In addition, the Amendment provides us with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with the Amendment, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. As a result of this issuance, we redeemed $201.7 million of the 2010 Senior Notes in December 2013 and the balance of $48.3 million in January 2014 and repaid approximately $120.0 million toward our 2012 Term Loan.

Operating Activities

Net cash provided by operating activities was $80.9 million for the nine months ended December 31, 2013 compared to $100.9 million for the nine months ended December 31, 2012. The $20.0 million decrease in net cash provided by operating activities was primarily due to an increase in working capital of $24.0 million, and a decrease in non-cash charges of $6.4 million, offset partly by an increase in net income of $10.5 million.

Working capital is defined as current assets (excluding cash and cash equivalents) minus current liabilities. Working capital increased primarily due to decreases in accrued liabilities of $23.1 million and accounts payable of $15.4 million and increases

- 43-

to prepaid expenses of $8.6 million, partially offset by decreases in accounts receivable of $22.0 million and inventories of $1.1 million.

Non-cash charges decreased $6.4 million primarily due to a premium payment on the 2010 Senior Notes tendered of $12.8 million, a decrease in deferred income tax charges of $5.7 million, and increases in amortization of deferred financing charges and debt discount of $3.0 million. The decrease in non-cash charges were partially offset by a $15.0 million loss on extinguishment of debt.

Investing Activities

Net cash used in investing activities was $57.9 million for the nine months ended December 31, 2013 compared to the net cash provided by investing activities of $12.6 million for the nine months ended December 31, 2012. The increase in net cash used in investing activities for the nine months ended December 31, 2013 was primarily due to the use of cash for the Care Pharma acquisition in July 2013 and the receipt of proceeds from the sale of the Phazyme brand in the prior year.

Financing Activities

Net cash provided by financing activities was $55.5 million for the nine months ended December 31, 2013 compared to $122.0 million used in financing activities for the nine months ended December 31, 2012. The increase in cash provided by financing activities was primarily due to the proceeds from the issuance of the 2013 Senior Notes of $400.0 million, which was offset by the payment of 2010 Senior Notes of $201.7 million and payments toward the 2012 Term Loan of $147.5 million. During the nine months ended December 31, 2013, we had net borrowings of $4.5 million against our 2012 ABL Revolver. Due to the issuance of the 2013 Senior Notes, our outstanding indebtedness increased to $1,033.3 million at December 31, 2013 from $978.0 million at March 31, 2013.



	Nine Months Ended December 31,
(In thousands)	2013			2012
Cash provided by (used in):
Operating Activities	$	80,860		$	100,876
Investing Activities	(57,870		)	12,567
Financing Activities	55,542			(122,040		)

Capital Resources

The 2010 Senior Notes were issued at an aggregate face value of $150.0 million with a discount to note-holders of $2.2 million and net proceeds to us of $147.8 million. The discount was offered to improve the yield to maturity to lenders reflective of market conditions at the time of the offering. In addition to the discount, we incurred $7.3 million of costs primarily related to fees of bank arrangers and legal advisors, of which $6.6 million was capitalized as deferred financing costs and $0.7 million was expensed as incurred. On December 17, 2013, we offered to redeem the 2010 Senior Notes at a premium of 6.33%, of which $201.7 million were redeemed on such date. The remaining $48.3 million were redeemed on January 16, 2014. As a result, we recorded a $15.0 million loss on the early extinguishment of the $201.7 million 2010 Senior Notes redeemed and will record a loss of approximately $3.3 million on the remaining $48.3 million tendered on January 16, 2014.

On January 31, 2012, in connection with the acquisition of the GSK Brands, we (i) issued the 2012 Senior Notes in an aggregate principal amount of $250.0 million, (ii) entered into the 2012 Term Loan with a seven-year maturity and the 2012 ABL Revolver with a five-year maturity, and (iii) repaid in full and canceled the outstanding 2010 Credit Facility. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Company of $650.1 million. In addition to the discount, we incurred $33.3 million in issuance costs, which were capitalized as deferred financing costs and are being amortized over the terms of the related loans and notes.

As of December 31, 2013, we had an aggregate of $1,033.3 million of outstanding indebtedness, which consisted of the following:


•	$48.3 million of 8.25% 2010 Senior Notes due 2018;


•	$250.0 million of 8.125% 2012 Senior Notes due 2020;


•	$400.0 million of 5.375% 2013 Senior Notes due 2021;


•	$297.5 million of borrowings under the 2012 Term Loan; and


•	$37.5 million of borrowings under the 2012 ABL Revolver.

As of December 31, 2013, we had $57.5 million of borrowing capacity under the 2012 ABL Revolver, as amended.

- 44-

Borrowings under the 2012 ABL Revolver bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments in an amount set forth in the credit agreement covering the 2012 ABL Revolver.

As we deem appropriate, we may from time to time utilize derivative financial instruments to mitigate the impact of changing interest rates associated with our long-term debt obligations or other derivative financial instruments. While we have utilized derivative financial instruments in the past, we did not have any derivative financial instruments outstanding at either December 31, 2013 or March 31, 2013 or during any of the periods presented. We have not entered into derivative financial instruments for trading purposes; all of our derivatives were over-the-counter instruments with liquid markets.

Our debt facilities contain various financial covenants, including provisions that require us to maintain certain leverage, interest coverage and fixed charge ratios. The senior secured credit facility and the indentures governing the 2010 Senior Notes, 2012 Senior Notes, and 2013 Senior Notes contain provisions that accelerate our indebtedness on certain changes in control and restrict us from undertaking specified corporate actions, including asset dispositions, acquisitions, payment of dividends and other specified payments, repurchasing our equity securities in the public markets, incurrence of indebtedness, creation of liens, making loans and investments and transactions with affiliates. Specifically, we must:

•

Have a leverage ratio of less than 6.75 to 1.0 for the quarter ended December 31, 2013 (defined as, with certain adjustments, the ratio of our consolidated total net debt as of the last day of the fiscal quarter to our trailing twelve month consolidated net income before interest, taxes, depreciation, amortization, non-cash charges and certain other items (“EBITDA”)). Our leverage ratio requirement decreases over time to 3.50 to 1.0 for the quarter ending June 30, 2016, and remains level thereafter;


•	Have an interest coverage ratio of greater than 1.7 to 1.0 for the quarter ended December 31, 2013 (defined as, with certain adjustments, the ratio of our consolidated EBITDA to our trailing twelve month consolidated cash interest expense). Our interest coverage requirement increases over time to 2.50 to 1.0 for the quarter ending June 30, 2016, and remains level thereafter; and


•	Have a fixed charge ratio of greater than 1.0 to 1.0 for the quarter ended December 31, 2013 (defined as, with certain adjustments, the ratio of our consolidated EBITDA minus capital expenditures to our trailing twelve month consolidated interest paid, taxes paid and other specified payments). Our fixed charge requirement remains level throughout the term of the agreement.

At December 31, 2013, we were in compliance with the applicable financial and restrictive covenants under the 2012 Term Loan and 2012 ABL Revolver and the indentures governing the 2010 Senior Notes, 2012 Senior Notes, and 2013 Senior Notes. Additionally, management anticipates that in the normal course of operations, we will be in compliance with the financial and restrictive covenants during the ensuing year.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements or financing activities with special-purpose entities.

- 45-

Inflation

Inflationary factors such as increases in the costs of raw materials, packaging materials, purchased product and overhead may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial condition or results from operations for the periods referred to above, a high rate of inflation in the future could have a material adverse effect on our financial condition or results from operations. The recent volatility in crude oil prices has had an adverse impact on transportation costs, as well as certain petroleum based raw materials and packaging material. Although we make efforts to minimize the impact of inflationary factors, including raising prices to our customers, a high rate of pricing volatility associated with crude oil supplies or other raw materials used in our products may have an adverse effect on our operating results.

- 46-

Critical Accounting Policies and Estimates

Our significant accounting policies are described in the notes to the unaudited Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q, as well as in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013. While all significant accounting policies are important to our Consolidated Financial Statements, certain of these policies may be viewed as being critical. Such policies are those that are both most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, or the related disclosure of contingent assets and liabilities. These estimates are based upon our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different conditions. The most critical accounting estimates are described below.

Revenue Recognition

We recognize revenue when the following revenue recognition criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of risk of loss generally occurs when product is received by the customer and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Direct reimbursements of advertising costs are reflected as a reduction of advertising costs in the periods in which the reimbursement criteria are achieved. We do not provide incentives to customers for the acquisition of product in excess of normal inventory quantities, because such incentives increase the potential for future returns, as well as reduce sales in the subsequent fiscal periods. Estimates of costs of promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of the promotional program, the estimated amounts are adjusted to actual results. Our related promotional expense for the fiscal year ended March 31, 2013 was $35.6 million. For the three and nine months ended December 31, 2013, our related promotional expense was $8.4 million and $21.3 million, respectively. We believe that the estimation methodologies employed, combined with the nature of the promotional campaigns, make the likelihood remote that our obligation would be misstated by a material amount. However, for illustrative purposes, had we underestimated the promotional program rate by 10% for the fiscal year ended March 31, 2013, our sales and operating income would have been adversely affected by approximately $3.6 million. Net income would have been adversely affected by approximately $2.2 million. Similarly, had we underestimated the promotional program rate by 10% for the three and nine months ended December 31, 2013, our sales and operating income would have been adversely affected by approximately $0.8 million and $2.1 million, respectively. Net income would have been adversely affected by approximately $0.3 million and $1.3 million, respectively, for the three and nine months ended December 31, 2013.

We also periodically run coupon programs in Sunday newspaper inserts, on our product website or as on-package instant redeemable coupons. We utilize a national clearinghouse to process coupons redeemed by customers. At the time a coupon is distributed, a provision is made based upon historical redemption rates for that particular product, information provided as a result of the clearinghouse's experience with coupons of similar dollar value, the length of time the coupon is valid, and the seasonality of the coupon drop, among other factors. During the fiscal year ended March 31, 2013, we had 263 coupon events. The amount recorded against revenues and accrued for these events during 2013 was $8.3 million. Cash settlement of coupon redemptions during 2013 was $7.3 million. During the three and nine months ended December 31, 2013, we had 74 and 188 coupon events, respectively. The amount recorded against revenue and accrued for these events during the three and nine months ended December 31, 2013 was $0.6 million and $1.8 million, respectively. Cash settlement of coupon redemptions during the three and nine months ended December 31, 2013 was $1.5 million and $3.4 million, respectively.

Allowances for Product Returns

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with the recording of sales. Such estimates are made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

- 47-

We construct our returns analysis by looking at the previous year's return history for each brand. Subsequently, each month, we estimate our current return rate based upon an average of the previous six months' return rate and review that calculated rate for reasonableness, giving consideration to the other factors described above. Our historical return rate has been relatively stable; for example, for the fiscal years ended March 31, 2013, 2012 and 2011, returns represented 2.9%, 2.9% and 2.7%, respectively, of gross sales. For the three and nine months December 31, 2013, product returns represented 1.9% and 2.6% of gross sales, respectively. At December 31, 2013 and March 31, 2013, the allowance for sales returns and cash discounts was $8.1 million and $6.4 million, respectively.

While we utilize the methodology described above to estimate product returns, actual results may differ materially from our estimates, causing our future financial results to be adversely affected. Among the factors that could cause a material change in the estimated return rate would be significant unexpected returns with respect to a product or products that comprise a significant portion of our revenues. Based upon the methodology described above and our actual returns experience, management believes the likelihood of such an event remains remote. Over the last three years, our actual product return rate has stayed within a range of 3.6% to 1.9% of gross sales. However, a hypothetical increase of 0.1% in our estimated return rate as a percentage of gross sales would have adversely affected our reported sales and operating income for the fiscal year ended March 31, 2013 by approximately $1.0 million. Net income would have been adversely affected by approximately $0.6 million. A hypothetical increase of 0.1% in our estimated return rate as a percentage of gross sales for the three and nine months ended December 31, 2013 would have adversely affected our reported sales and operating income by approximately $0.1 million and $0.5 million, respectively, while our net income would have been adversely affected by approximately $0.1 million and $0.4 million, respectively.

Lower of Cost or Market for Obsolete and Damaged Inventory

We value our inventory at the lower of cost or market value. Accordingly, we reduce our inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Many of our products are subject to expiration dating. As a general rule, our customers will not accept goods with expiration dating of less than 12 months from the date of delivery. To monitor this risk, management utilizes a detailed compilation of inventory with expiration dating between zero and 15 months and reserves for 100% of the cost of any item with expiration dating of 12 months or less. Inventory obsolescence costs charged to operations were $3.2 million for the fiscal year ended March 31, 2013, while for the three and nine months ended December 31, 2013, we recorded obsolescence costs of $0.4 million and $1.9 million, respectively. A hypothetical increase of 1.0% in our allowance for obsolescence at March 31, 2013 would have adversely affected our reported operating income and net income for the fiscal year ended March 31, 2013 by approximately $0.3 million and $0.1 million, respectively. Similarly, a hypothetical increase of 1.0% in our obsolescence allowance for the three and nine months ended December 31, 2013 would have adversely affected each of our reported operating income and net income by less than approximately $0.1 million and $0.2 million, respectively.

Allowance for Doubtful Accounts

In the ordinary course of business, we grant non-interest bearing trade credit to our customers on normal credit terms. We maintain an allowance for doubtful accounts receivable, which is based upon our historical collection experience and expected collectability of the accounts receivable. In an effort to reduce our credit risk, we (i) establish credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of our customers' financial condition, (iii) monitor the payment history and aging of our customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

We establish specific reserves for those accounts that file for bankruptcy, have no payment activity for 180 days or have reported major negative changes to their financial condition. The allowance for bad debts amounted to 1.6% and 1.1% of accounts receivable at December 31, 2013 and March 31, 2013, respectively. Bad debt expense for the fiscal year ended March 31, 2013 was $0.3 million, while during the three and nine months ended December 31, 2013, we recorded bad debt expense of less than $0.1 million and $0.1 million, respectively.

While management believes that it is diligent in its evaluation of the adequacy of the allowance for doubtful accounts, an unexpected event, such as the bankruptcy filing of a major customer, could have an adverse effect on our future financial results. A hypothetical increase of 0.1% in our bad debt expense as a percentage of net sales during the fiscal year ended March 31, 2013 would have resulted in a decrease in reported operating income of approximately $0.6 million and a decrease in our reported net income of approximately $0.4 million. Similarly, a hypothetical increase of 0.1% in our bad debt expense as a percentage of sales for the three and nine months ended December 31, 2013 would have resulted in a decrease in reported operating income and net income of less than $0.1 million in each period.

- 48-

Valuation of Intangible Assets and Goodwill

Goodwill and intangible assets amounted to $1,585.7 million and $1,540.8 million at December 31, 2013 and March 31, 2013, respectively. At December 31, 2013, goodwill and intangible assets were apportioned among our two operating segments as follows:



(In thousands)	OTC Healthcare		Household Cleaning		Consolidated

Goodwill	$	182,566	$	7,389	$	189,955

Intangible assets, net
Indefinite-lived:
Analgesics	343,518		—		343,518
Cough & Cold	207,723		—		207,723
Gastrointestinal	215,946		—		215,946
Eye & Ear Care	172,318		—		172,318
Dermatologicals	149,927		—		149,927
Oral Care	61,438		—		61,438
Other OTC	1,954		—		1,954
Household Cleaning	—		119,820		119,820
Total indefinite-lived intangible assets, net	1,152,824		119,820		1,272,644

Finite-lived:
Analgesics	4,169		—		4,169
Cough & Cold	21,911		—		21,911
Gastrointestinal	12,572		—		12,572
Eye & Ear Care	8,172		—		8,172
Dermatologicals	5,689		—		5,689
Oral Care	17,536		—		17,536
Other OTC	26,459		—		26,459
Household Cleaning	—		26,603		26,603
Total finite-lived intangible assets, net	96,508		26,603		123,111
Total intangible assets, net	1,249,332		146,423		1,395,755
Total goodwill and intangible assets, net	$	1,431,898	$	153,812	$	1,585,710

Our Chloraseptic, Clear Eyes, Compound W, Dramamine, Efferdent, Luden's, PediaCare, BC, Goody's, Ecotrin, Beano, Gaviscon, Tagamet, Fiber Choice, Sominex and Debrox brands comprise the majority of the value of the intangible assets within the OTC Healthcare segment. The Chore Boy, Comet, and Spic and Span brands comprise substantially all of the intangible asset value within the Household Cleaning segment.

On July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we allocated $31.5 million to intangible assets based on our preliminary analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition.

In connection with the Care Pharma acquisition, we also recorded goodwill based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The amount of goodwill deductible for tax purposes is $23.1 million.

Goodwill and intangible assets comprise substantially all of our assets. Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a purchase business combination. Intangible assets generally represent our trademarks, brand names and patents. When we acquire a brand, we are required to make judgments regarding the value assigned to the associated intangible assets, as well as their respective useful lives. Management considers many factors both prior to and after the acquisition of an intangible asset in determining the value, as well as the useful life, assigned to each intangible asset that we acquire or continue to own and promote.

- 49-

The most significant factors are:


•	Brand History

A brand that has been in existence for a long period of time (e.g., 25, 50 or 100 years) generally warrants a higher valuation and longer life (sometimes indefinite) than a brand that has been in existence for a very short period of time. A brand that has been in existence for an extended period of time generally has been the subject of considerable investment by its previous owner(s) to support product innovation and advertising and promotion.


•	Market Position

Consumer products that rank number one or two in their respective market generally have greater name recognition and are known as quality product offerings, which warrant a higher valuation and longer life than products that lag in the marketplace.


•	Recent and Projected Sales Growth

Recent sales results present a snapshot as to how the brand has performed in the most recent time periods and represent another factor in the determination of brand value. In addition, projected sales growth provides information about the strength and potential longevity of the brand. A brand that has both strong current and projected sales generally warrants a higher valuation and a longer life than a brand that has weak or declining sales. Similarly, consideration is given to the potential investment, in the form of advertising and promotion that is required to reinvigorate a brand that has fallen from favor.


•	History of and Potential for Product Extensions

Consideration also is given to the product innovation that has occurred during the brand's history and the potential for continued product innovation that will determine the brand's future. Brands that can be continually enhanced by new product offerings generally warrant a higher valuation and longer life than a brand that has always “followed the leader”.

After consideration of the factors described above, as well as current economic conditions and changing consumer behavior, management prepares a determination of the intangible assets' values and useful lives based on its analysis. Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. In a similar manner, indefinite-lived assets are no longer amortized. They are also subject to an annual impairment test, or more frequently if events or changes in circumstances indicate that the asset's carrying value more likely than not exceeds its fair market value. Additionally, at each reporting period an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and must also be tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis, during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to goodwill and intangible assets and tests for impairment.

We report goodwill and indefinite-lived intangible assets in two operating segments: OTC Healthcare and Household Cleaning. We identify our reporting units in accordance with the FASB ASC Subtopic 280-10, which is at the brand level, and one level below the operating segment level. The carrying value and fair value for intangible assets and goodwill for a reporting unit are calculated based on the key assumptions and valuation methodologies previously discussed. As a result, any material changes to these assumptions could require us to record additional impairment in the future.

Goodwill

As of March 31, 2013, we had 15 reporting units with goodwill, including six reporting units resulting from the acquisition of the GSK Brands. The aggregate fair value exceeded the carrying value by 57.6%. Two individual reporting unit's fair value exceeded their carrying values by less than 10.0%. The Company has experienced revenue declines in regard to certain brands in its Household Cleaning segment during 2013, 2012, and 2011. Adverse changes in the expected operating results and/or unfavorable changes in other economic factors used to estimate fair values of these specific brands could result in a non-cash impairment charge in the future. As part of our annual test for impairment of goodwill, management estimates the discounted cash flows of each reporting unit, which is at the brand level, and one level below the operating segment level, to estimate their respective fair values. In performing this analysis, management considers the same types of information as listed below with regard to finite-lived intangible assets. In the event that the carrying amount of the reporting unit exceeds the fair value, management would then be required to allocate the estimated fair value of the assets and liabilities of the reporting unit as if the unit was acquired in a business combination, thereby revaluing the carrying amount of goodwill. Future events, such as competition, technological

- 50-

advances and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions, and we may be required to record additional impairment charges in the future. However, no impairment charge was recorded during the nine months ended December 31, 2013.

Indefinite-Lived Intangible Assets

In a manner similar to finite-lived intangible assets, at each reporting period, management analyzes current events and circumstances to determine whether the indefinite life classification for a trademark or trade name continues to be valid. If circumstances warrant a change to a finite life, the carrying value of the intangible asset would then be amortized prospectively over the estimated remaining useful life.

Management tests the indefinite-lived intangible assets for impairment by comparing the carrying value of the intangible asset to its estimated fair value. Since quoted market prices are seldom available for trademarks and trade names such as ours, we utilize present value techniques to estimate fair value. Accordingly, management's projections are utilized to assimilate all of the facts, circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life. In performing this analysis, management considers the same types of information as listed below with regard to finite-lived intangible assets. Once that analysis is completed, a discount rate is applied to the cash flows to estimate fair value. In a manner similar to goodwill, future events, such as competition, technological advances and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions.

Finite-Lived Intangible Assets

As mentioned above, when events or changes in circumstances indicate the carrying value of the assets may not be recoverable, management performs a review to ascertain the impact of events and circumstances on the estimated useful lives and carrying values of our trademarks and trade names. In connection with this analysis, management:


•	Reviews period-to-period sales and profitability by brand;


•	Analyzes industry trends and projects brand growth rates;


•	Prepares annual sales forecasts;


•	Evaluates advertising effectiveness;


•	Analyzes gross margins;


•	Reviews contractual benefits or limitations;


•	Monitors competitors' advertising spend and product innovation;


•	Prepares projections to measure brand viability over the estimated useful life of the intangible asset; and


•	Considers the regulatory environment, as well as industry litigation.

If analysis of any of the aforementioned factors warrants a change in the estimated useful life of the intangible asset, management will reduce the estimated useful life and amortize the carrying value prospectively over the shorter remaining useful life. Management's projections are utilized to assimilate all of the facts, circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life. In the event that the long-term projections indicate that the carrying value is in excess of the undiscounted cash flows expected to result from the use of the intangible assets, management is required to record an impairment charge. Once that analysis is completed, a discount rate is applied to the cash flows to estimate fair value. The impairment charge is measured as the excess of the carrying amount of the intangible asset over fair value, as calculated using the discounted cash flow analysis. Future events, such as competition, technological advances and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions.

Impairment Analysis

We estimate the fair value of our intangible assets and goodwill using a discounted cash flow method. This discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently. In addition, we considered our market capitalization at March 31, 2013, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. As a result of our analysis, we did not record an impairment charge during the three months ended March 31, 2013.

The discount rate utilized in the analysis, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of goodwill and intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future. However, no impairment charge was recorded during the nine months ended December 31, 2013.

- 51-

Stock-Based Compensation

The Compensation and Equity topic of the FASB ASC requires us to measure the cost of services to be rendered based on the grant-date fair value of an equity award. Compensation expense is to be recognized over the period during which an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. Information utilized in the determination of fair value includes the following:


•	Type of instrument (i.e., restricted shares vs. an option, warrant or performance shares);


•	Strike price of the instrument;


•	Market price of our common stock on the date of grant;


•	Discount rates;


•	Duration of the instrument; and


•	Volatility of our common stock in the public market.

Additionally, management must estimate the expected attrition rate of the recipients to enable it to estimate the amount of non-cash compensation expense to be recorded in our financial statements. While management uses diligent analysis to estimate the respective variables, a change in assumptions or market conditions, as well as changes in the anticipated attrition rates, could have a significant impact on the future amounts recorded as non-cash compensation expense. We recorded non-cash compensation expense of $3.8 million and $3.0 million for the nine months ended December 31, 2013 and 2012, respectively.

Loss Contingencies

Loss contingencies are recorded as liabilities when it is probable that a liability has been incurred and the amount of such loss is reasonably estimable. Contingent losses are often resolved over longer periods of time and involve many factors, including:


•	Rules and regulations promulgated by regulatory agencies;


•	Sufficiency of the evidence in support of our position;


•	Anticipated costs to support our position; and


•	Likelihood of a positive outcome.

Recent Accounting Pronouncements

In July 2013, the FASB issued ASU 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which requires that an unrecognized tax benefit, or portion of an unrecognized tax benefit, be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. If an applicable deferred tax asset is not available to use or the tax law of the applicable jurisdiction does not require the entity to use and the company does not intend to use the applicable deferred tax asset, the unrecognized tax benefit should be presented as a liability in the financial statements and should not be combined with an unrelated deferred tax asset. ASU 2013-11 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date; however, retrospective application is permitted. The adoption of ASU 2013-11 is not expected to have a material impact on our Consolidated Financial Statements.

In March 2013, the FASB issued ASU 2013-05, Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, relating to the release of cumulative translation adjustments into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on our Consolidated Financial Statements.

In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires that for those items that are reclassified out of accumulated other comprehensive income and into net income in their entirety, the effect of the reclassification on each affected net income line item be disclosed. For accumulated other comprehensive income reclassification items that are not reclassified in their entirety into net income, a cross reference must be made to other required disclosures. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. ASU 2013-02 did not have a material impact on our Consolidated Financial Statements. See Note 13, Accumulated Other Comprehensive Loss, to our Consolidated Financial Statements for required disclosure.

- 52-

subject to an agreement similar to a master netting arrangement. In addition, the standard requires disclosure of collateral received and posted in connection with master netting agreements or similar arrangements. An entity will be required to disclose the following information for assets and liabilities within the scope of the new standard: (i) the gross amounts of those recognized assets and those recognized liabilities; (ii) the amounts offset to determine the net amounts presented in the statement of financial position; (iii) the net amounts presented in the statement of financial position; (iv) the amounts subject to an enforceable master netting arrangement or similar agreement not otherwise included in (ii); and (v) the net amount after deducting the amounts in (iv) from the amounts in (iii). The standard affects all entities with balances presented on a net basis in the financial statements, derivative assets and derivative liabilities, repurchase agreements, and financial assets and financial liabilities executed under a master netting or similar arrangement. This guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. This new guidance did not have a material impact on our Consolidated Financial Statements.

- 53-

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), including, without limitation, information within Management's Discussion and Analysis of Financial Condition and Results of Operations. The following cautionary statements are being made pursuant to the provisions of the PSLRA and with the intention of obtaining the benefits of the “safe harbor” provisions of the PSLRA. Although we believe that our expectations are based on reasonable assumptions, actual results may differ materially from those in the forward-looking statements.

Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required under federal securities laws and the rules and regulations of the SEC, we do not have any intention to update any forward-looking statements to reflect events or circumstances arising after the date of this Quarterly Report on Form 10-Q, whether as a result of new information, future events or otherwise. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements included in this Quarterly Report on Form 10-Q or that may be made elsewhere from time to time by, or on behalf of, us. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

These forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “anticipate,” “expect,” “estimate,” “project,” "intend," "strategy," "future," "seek," "may," "would," "will," “will be,” or other similar words and phrases. Forward-looking statements and our plans and expectations are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, and our business in general is subject to such risks. For more information, see “Risk Factors” contained in Part I, Item 1A., of our Annual Report on Form 10-K for our fiscal year ended March 31, 2013 and in Part II, Item 1A. of this Quarterly Report on Form 10-Q. In addition, our expectations or beliefs concerning future events involve risks and uncertainties, including, without limitation:


•	The high level of competition in our industry and markets;


•	Our ability to increase organic growth via new product introductions or line extensions;


•	Our ability to invest successfully in research and development;


•	Our dependence on a limited number of customers for a large portion of our sales;


•	Changes in inventory management practices by retailers;


•	Our expectations regarding increased advertising and promotion spending for acquired brands;


•	Our ability to grow our international sales;


•	General economic conditions affecting sales of our products and their respective markets;


•	Business, regulatory and other conditions affecting retailers;


•	Changing consumer trends or pricing pressures which may cause us to lower our prices;


•	Our dependence on third-party manufacturers to produce the products we sell;


•	Price increases for raw materials, labor, energy and transportation costs;


•	Disruptions in our distribution center;


•	Acquisitions, dispositions or other strategic transactions diverting managerial resources, the incurrence of additional liabilities or integration problems associated with such transactions;


•	Actions of government agencies in connection with our products or regulatory matters governing our industry;


•	Product liability claims, product recalls and related negative publicity;


•	Our ability to protect our intellectual property rights;


•	Our dependence on third parties for intellectual property relating to some of the products we sell;


•	Our assets being comprised virtually entirely of goodwill and intangibles and possible changes in their value;


•	Our dependence on key personnel;


•	Shortages of supply of sourced goods or interruptions in the manufacturing of our products;


•	The costs associated with any claims in litigation or arbitration and any adverse judgments rendered in such litigation or arbitration;


•	Our level of indebtedness, and possible inability to service our debt;


•	Our ability to obtain additional financing; and


•	The restrictions imposed by our financing agreements on our operations.

- 54-


ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in interest rates because our 2012 Term Loan and 2012 ABL Revolver are variable rate debt. Interest rate changes generally do not significantly affect the market value of the 2012 Term Loan and the 2012 ABL Revolver but do affect the amount of our interest payments and, therefore, our future earnings and cash flows, assuming other factors are held constant. At December 31, 2013, we had variable rate debt of approximately $297.5 million under our 2012 Term Loan and $37.5 million under our 2012 ABL Revolver.

Holding other variables constant, including levels of indebtedness, a one percentage point increase in interest rates on our variable rate debt would have an adverse impact on pre-tax earnings and cash flows for the three and nine months ended December 31, 2013 of approximately $0.8 million and $6.6 million, respectively.


ITEM 4.	CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company's management, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a–15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of December 31, 2013. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2013, the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the three months ended December 31, 2013, the Company completed the implementation of the first phase of its new ERP. Management believes appropriate internal controls were maintained during the process. As appropriate, the Company is modifying the design and documentation of internal control processes and procedures relating to the new system to simplify and harmonize existing internal controls over financial reporting. There have been no other significant changes during the quarter ended December 31, 2013 in the Company's internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

The Company plans to continue to enhance the effectiveness of the system by utilizing additional modules and integrating additional software with SAP. These enhancements are expected to replace legacy systems and integrate with the core financial modules mentioned above over the next several years.


PART II.	OTHER INFORMATION

ITEM 1A. RISK FACTORS

In addition to the risk factors set forth below and the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended March 31, 2013, which could materially affect our business, financial condition or future results. The risks described below and in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and results of operations. The information below amends, updates and should be read in conjunction with the risk factors and information disclosed in our Annual Report on Form 10-K for the year ended March 31, 2013.

The high level of competition in our industry, much of which comes from competitors with greater resources, could adversely affect our business, financial condition and results from operations.

The business of selling brand name consumer products in the OTC Healthcare and Household Cleaning categories is highly competitive. These markets include numerous manufacturers, distributors, marketers and retailers that actively compete for consumers’ business both in the United States and abroad. Many of these competitors are larger and have substantially greater resources than we do, and may therefore have the ability to spend more aggressively on research and development, advertising and marketing, and to respond more effectively to changing business and economic conditions. If this were to occur, it could have a material adverse effect on our business, financial condition and results from operations.

- 55-

We compete for customers’ attention based on a number of factors, including brand recognition, product quality, performance, price and product availability at the retail level. Advertising, promotion, merchandising and packaging and the timing of new product introductions and line extensions also have a significant impact on consumer buying decisions and, as a result, on our sales. Additionally, the return to the market of previously recalled competitive products could impact our sales. The structure and quality of our sales force, as well as sell-through of our products, affect the continued offering of our products, in-store position, wall display space and inventory levels in retail stores. If we are unable to maintain our current distribution network, product offerings in retail stores, inventory levels and in-store positioning of our products, our sales and operating results will be adversely affected. Our markets also are highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market. An increase in the number of product innovations by our competitors or the failure of a new product launch by the Company could have a material adverse effect on our business, financial condition and results from operations.

In addition, competitors may attempt to gain market share by offering products at prices at or below those typically offered by us. Competitive pricing may require us to reduce prices, which may result in lost sales or a reduction of our profit margins. Future price adjustments, product changes or new product introductions by our competitors or our inability to react with price adjustments, product changes or new product introductions of our own could result in a loss of market share, which could have a material adverse effect on our business, financial condition and results from operations.

We depend on a limited number of customers with whom we have no long-term agreements for a large portion of our gross sales and the loss of one or more of these customers could reduce our gross sales and have a material adverse effect on our business, financial condition and results of operations.

For the three and nine months ended December 31, 2013, Walmart, which accounted for approximately 20.4% and 19.7%, respectively, of our gross sales, was our only customer that accounted for 10% or more of our sales. We expect that for future periods, our top five and ten customers, including Walmart, will, in the aggregate, continue to account for a large portion of our sales. The loss of one or more of our top customers, any significant decrease in sales to these customers based on inventory management or otherwise, or a significant decrease in our retail display space in any of these customers’ stores, could reduce our sales and have a material adverse effect on our business, financial condition and results from operations. In addition, the introduction or expansion of store brand products that compete with our products has impacted and could in the future impact our sales and results from operations.

In addition, our business is based primarily upon individual sales orders. We typically do not enter into long-term contracts with our customers. Accordingly, our customers could cease buying products or reduce the number of items they buy from us at any time and for any reason. The fact that we do not have long-term contracts with our customers means that we have no recourse in the event a customer no longer wants to purchase products from us or reduces the number of items purchased. If a significant number of our smaller customers, or any of our significant customers, elect not to purchase products from us, our business, financial condition and results from operations could be adversely affected.

Our annual and quarterly results from operations may fluctuate significantly and could fall below the expectations of securities analysts and investors due to a number of factors, many of which are beyond our control, resulting in a decline in the price of our securities.

Our annual and quarterly results from operations may fluctuate significantly because of numerous factors, including:


•	Increases and decreases in quarterly revenues and profitability;


•	The timing of when we make acquisitions or introduce new products;


•	Our inability to increase the sales of our existing products and expand their distribution;


•	The timing of the introduction or return to the market of competitive products and the introduction of store brand products;


•	Adverse regulatory actions or market events in the United States or in our international markets;


•	Changes in consumer preferences, spending habits and competitive conditions, including the effects of competitors’ operational, promotional or expansion activities;


•	Seasonality of our products;

- 56-


•	Fluctuations in commodity prices, product costs, utilities and energy costs, prevailing wage rates, insurance costs and other costs;


•	The discontinuation and return of our products from retailers;


•	Our ability to recruit, train and retain qualified employees, and the costs associated with those activities;


•	Changes in advertising and promotional activities and expansion to new markets;


•	Negative publicity relating to us and the products we sell;


•	Litigation matters;


•	Unanticipated increases in infrastructure costs;


•	Impairment of goodwill or long-lived assets;


•	Changes in interest rates; and


•	Changes in accounting, tax, regulatory or other rules applicable to our business.

Our quarterly operating results and revenues may fluctuate as a result of any of these or other factors. Accordingly, results for any one quarter are not necessarily indicative of results to be expected for any other quarter or for any year, and revenues for any particular future period may decrease. In the future, operating results may fall below the expectations of securities analysts and investors. In that event, the market price of our outstanding securities could be adversely impacted.

We depend on third-party manufacturers to produce the products we sell. If we are unable to maintain these manufacturing relationships or fail to enter into additional relationships, as necessary, we may be unable to meet customer demand and our sales and profitability could suffer as a result.

All of our products are produced by third-party manufacturers. Our ability to retain our current manufacturing relationships and engage in and successfully transition to new relationships is critical to our ability to deliver quality products to our customers in a timely manner. Without adequate supplies of quality merchandise, sales would decrease materially and our business would suffer. In the event that our primary third-party manufacturers are unable or unwilling to ship products to us in a timely manner, we would have to rely on secondary manufacturing relationships or identify and qualify new manufacturing relationships. We might not be able to identify or qualify such manufacturers for existing or new products in a timely manner, and such manufacturers may not allocate sufficient capacity to us in order that we may meet our commitments to customers. In addition, identifying alternative manufacturers without adequate lead times can compromise required product validation and stability protocol, which may involve additional manufacturing expense, delay in production or product disadvantage in the marketplace. In general, the consequences of not securing adequate, high quality and timely supplies of merchandise would negatively impact inventory levels, sales and gross margins, and could have a material adverse effect on our business, financial condition and results from operations.

The manufacturers we use may also increase the cost of the products we purchase which could adversely affect our margins in the event we are unable to pass along these increased costs to our customers. A situation such as this could also have a material adverse effect on our business, financial condition and results from operations.

At December 31, 2013, we had relationships with 58 third-party manufacturers pertaining to our domestic operations. Of those, we had long-term contracts with 21 manufacturers that produced items that accounted for approximately 86.3% of our gross sales for 2013. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing these products at any time and for any reason or initiate arbitrary and costly price increases, either of which could have a material adverse effect on our business, financial condition and results from operations.

- 57-

Our risks associated with doing business internationally increase as we expand our international footprint.

During the three and nine months ended December 31, 2013, approximately 6.0% and 5.0%, respectively, of our total revenues were attributable to our international business. As of July 1, 2013, we acquired Care Pharmaceuticals, which markets and sells healthcare products in Australia. We generally rely on brokers and distributors for the sale of our products in other foreign countries. In addition to the risks associated with political instability, changes in the outlook for economic prosperity in these countries could adversely affect the sales of our products in these countries. Other risks of doing business internationally include:


•	Changes in the legislative or regulatory requirements of the countries or regions where we do business;


•	Currency controls that restrict or prohibit the payment of funds or the repatriation of earnings to the United States;


•	Fluctuating foreign exchange rates could result in unfavorable increases in the price of our products or cause increases in the cost of certain products purchased from our foreign third-party manufacturers;


•	Regulatory oversight and its impact on our ability to get products registered for sale in certain markets;


•	Potential trade restrictions and exchange controls;


•	Inability to protect our intellectual property rights in these markets; and


•	Increased costs of compliance with general business and tax regulations in these countries or regions.

Our indebtedness could adversely affect our financial condition, and the significant amount of cash we need to service our debt will not be available to reinvest in our business.

At December 31, 2013, our total indebtedness, including current maturities, was approximately $1,033.3 million.

Our indebtedness could:


•	Increase our vulnerability to general adverse economic and industry conditions;


•	Limit our ability to engage in strategic acquisitions;


•	Require us to dedicate a substantial portion of our cash flow from operations toward repayment of our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, acquisitions and investments and other general corporate purposes;


•	Limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we operate;


•	Place us at a competitive disadvantage compared to our competitors that have less debt; and


•	Limit, among other things, our ability to borrow additional funds on favorable terms or at all.

The terms of the indentures governing the 2010 Senior Notes, the 2012 Senior Notes and the 2013 Senior Notes, and the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver allow us to issue and incur additional debt upon satisfaction of conditions set forth in the respective agreements. If new debt is added to current debt levels, the related risks described above could increase.

At December 31, 2013, we had $57.5 million of borrowing capacity available under the 2012 ABL Revolver to support our operating activities.

- 58-

The senior credit facility and the indentures governing the senior notes contain cross-default provisions that could result in the acceleration of all of our indebtedness.

The senior credit facility and the indentures governing the senior notes contain provisions that allow the respective creditors to declare all outstanding borrowings under one agreement to be immediately due and payable as a result of a default under the other agreement. Consequently, under the senior credit facility, failure to make a payment required by the indentures governing the senior notes, among other things, may lead to an event of default under the senior credit facility. Similarly, an event of default or failure to make a required payment at maturity under the senior credit facility, among other things, may lead to an event of default under the indentures governing the senior notes. If the debt under the senior credit facility and indentures governing the senior notes were to both be accelerated, the aggregate amount immediately due and payable as of December 31, 2013 would have been approximately $1,029.8 million. We presently do not have sufficient liquidity to repay these borrowings in the event they were to be accelerated, and we may not have sufficient liquidity in the future to do so. Additionally, we may not be able to borrow money from other lenders to enable us to refinance our indebtedness. At December 31, 2013, the book value of our current assets was $244.5 million. Although the book value of our total assets was $1,864.8 million, approximately $1,585.7 million was in the form of intangible assets, including goodwill of $190.0 million, a significant portion of which may not be available to satisfy our creditors in the event our debt is accelerated.

Any failure to comply with the restrictions of the senior credit facility, the indentures governing the senior notes or any other subsequent financing agreements may result in an event of default. Such default may allow the creditors to accelerate the related debt, as well as any other debt to which the cross-acceleration or cross-default provisions apply. In addition, the lenders may be able to terminate any commitments they had made to supply us with additional funding. As a result, any default by us under our credit agreement, indentures governing the senior notes or any other financing agreement could have a material adverse effect on our financial condition.

Virtually all of our assets consist of goodwill and intangibles and are subject to impairment risk.

As our financial statements indicate, virtually all of our assets consist of goodwill and intangibles, principally the trademarks, trade names and patents that we have acquired. On an annual basis, and otherwise when there is evidence that events or changes in circumstances indicate, we assess the potential impairment of our goodwill. Upon any such evaluation, we may be required to record a significant charge in our financial statements, which would negatively impact or financial condition and results of operations. We recorded charges in 2010 and 2009 for impairment of certain assets. In the event that the value of those assets or other assets become further impaired or our financial condition is materially adversely affected in any way, we would not have tangible assets that could be sold to repay our liabilities. As a result, our creditors and investors may not be able to recoup the amount of the indebtedness that they have extended to us or the amount they have invested in us.

Our information technology systems may be susceptible to disruptions.

We utilize information technology systems to improve the effectiveness of our operations and support our business including systems to support financial reporting and an enterprise resource planning system, which we are currently implementing. During the implementation process, we could be subject to transaction errors, processing inefficiencies and other business disruptions that could lead to the loss of revenue or inaccuracies in our financial information. The occurrence of these or other challenges could disrupt our information technology systems and adversely affect our operations.

Changes in our provision for income taxes or adverse outcomes resulting from examination of our income tax returns could adversely affect our results.

Our provision for income taxes is subject to volatility and could be adversely affected by several factors, some of which are outside of our control, including:


•	changes in the income allocation methods for state taxes, and the determination of which states or countries have jurisdiction to tax our Company;


•	an increase in non-deductible expenses for tax purposes, including certain stock-based compensation, executive compensation and impairment of goodwill;


•	transfer pricing adjustments;


•	tax assessments resulting from income tax audits or any related tax interest or penalties that could significantly affect our income tax provision for the period in which the settlement takes place;

- 59-


•	a change in our decision to indefinitely reinvest foreign earnings;


•	changes in accounting principles; and


•	changes in tax laws or related interpretations, accounting standards, regulations, and interpretations in multiple tax jurisdictions in which we operate.

Significant judgment is required to determine the recognition and measurement attribute prescribed in FASB ASC 740. As a multinational corporation, we conduct our business in many countries and are subject to taxation in many jurisdictions. The taxation of our business is subject to the application of multiple and sometimes conflicting tax laws and regulations as well as multinational tax conventions. Our effective tax rate is dependent upon the availability of tax credits and carryforwards. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, and the evolution of regulations and court rulings. Consequently, taxing authorities may impose tax assessments or judgments against us that could materially impact our tax liability and/or our effective income tax rate.

In addition, we may be subject to examination of our income tax returns by the Internal Revenue Service and other tax authorities. If tax authorities challenge the relative mix of our U.S. and international income, or successfully assert the jurisdiction to tax our earnings, our future effective income tax rates could be adversely affected.

- 60-

ITEM 6. EXHIBITS

See Exhibit Index immediately following the signature page.

- 61-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		PRESTIGE BRANDS HOLDINGS, INC.


Date:	February 7, 2014	By:	/s/ RONALD M. LOMBARDI
			Ronald M. Lombardi
			Chief Financial Officer
			(Principal Financial Officer and
			Duly Authorized Officer)

- 62-

Exhibit Index




4.1			Indenture, dated as of December 17, 2013, among Prestige Brands, Inc., as issuer, the Company and certain subsidiaries, as guarantors, and U.S. Bank National Association, as Trustee with respect to 5.375% Senior Notes Due 2021.

4.2			Form of 5.375% Senior Note due 2021.

31.1			Certification of Principal Executive Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2			Certification of Principal Financial Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1			Certification of Principal Executive Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

32.2			Certification of Principal Financial Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
101.INS*			XBRL Instance Document
101.SCH*			XBRL Taxonomy Extension Schema Document
101.CAL*			XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*			XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*			XBRL Taxonomy Extension Label Linkbase Document
101.PRE*			XBRL Taxonomy Extension Presentation Linkbase Document

* XBRL information is furnished and not filed for purposes of Section 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement, prospectus or other document to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

- 63-